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Abstract
Gabapentin to reduce pain in women aged between 18 and
50 years with chronic pelvic pain: the GaPP2 RCT
Catherine A Hewitt ,1 Katy Vincent ,2 Lee J Middleton ,1
Liana Romaniuk ,3 Magda Koscielniak ,4 Ann M Doust ,4 Judy Birch ,5
Heather Whalley ,3 Jane P Daniels 6,7 and Andrew W Horne 4*
on behalf of the GaPP2 Collaborative Group
1Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham,
Birmingham, UK
2Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, UK
3Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
4Medical Research Council Centre for Reproductive Health, Queen’s Medical Research Institute,
University of Edinburgh, Edinburgh, UK
5Pelvic Pain Support Network, Poole, UK
6Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK
7Nottingham Health Sciences Partners, Queen’s Medical Centre, Nottingham, UK
*Corresponding author Andrew.horne@ed.ac.uk
Background: Chronic pelvic pain affects 2–24% of women worldwide, and evidence for medical
treatments is limited. Gabapentin is effective in treating some chronic pain conditions, but its effect on
central pain processing is unknown.
Objectives: To test the hypothesis that gabapentin can reduce pain and improve physical and
emotional functioning in women with chronic pelvic pain. We investigated the mechanism of action of
gabapentin in a subset of women.
Design: A randomised, double-blind, placebo-controlled, multicentre trial with a brain imaging substudy.
Setting: This trial took place in 39 UK hospitals.
Participants: A target of 300 women with a history of chronic pelvic pain in whom a laparoscopy
revealed no obvious pelvic pathology.
Intervention: Women were randomised to receive 300 mg of gabapentin (which was escalated to a
maximum of 2700 mg daily) or a matched placebo over a 4-week dose-escalation period, followed
by 12 weeks on optimal dose. A mechanistic substudy was also undertaken, in which a subset of
participants had a functional magnetic resonance imaging scan of their brain before and following
16 weeks of treatment.
Main outcome measures: The dual primary measure of the worst and average pelvic pain scores was
assessed weekly by a numerical rating scale (0–10) in weeks 13–16 post randomisation. The secondary
outcomes were patient-reported questionnaires, assessed physical functioning, fatigue, psychological
health, sexual activity, work and productivity, and pain catastrophising. Health-care resource use,
analgesic use and adverse events were also collected. The main outcome measure for the mechanistic
study was brain activity at rest and in response to noxious stimuli.
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Results: In the main trial, 306 participants were randomised. The mean worst pain score was 7.1
(standard deviation 2.6) in the gabapentin group and 7.4 (standard deviation 2.2) in the placebo group
(adjusted mean difference –0.20, 97.5% confidence interval –0.81 to 0.42; p = 0.47). The mean average
pain score was 4.3 (standard deviation 2.3) in the gabapentin group and 4.5 (standard deviation 2.2) in
the placebo group (adjusted mean difference –0.18, 97.5% confidence interval –0.71 to 0.35; p = 0.45).
No significant between-group differences were observed for any secondary outcome. A higher
proportion of women experienced a serious adverse event in the gabapentin group than in the placebo
group (10/153 vs. 3/153; p = 0.04). Dizziness, drowsiness and visual disturbances were more common
in the gabapentin group than in the placebo group. In the mechanistic study, 45 participants had a
baseline functional magnetic resonance imaging scan of their brain, with 25 participants returning for
a scan at the end of treatment. Gabapentin significantly decreased evoked activity in the anterior
cingulate cortex and cuneus. Change in anterior cingulate cortex activity after treatment related to
improvement on the pain interference scale, and baseline activation of this region predicted response
to treatment.
Conclusions: Gabapentin did not reduce pain and did not improve other outcomes compared with
placebo over 16 weeks. Serious adverse effects were significantly higher in the gabapentin group than
in the placebo group. Gabapentin reduces evoked activity in the anterior cingulate cortex, with changes
of activity in this region tracking reported pain, and baseline activity predicting response to treatment.
Limitations: Primary outcome data were unavailable in 62 and 60 women for the average and worst
numerical rating scale pain scores, respectively. A sensitivity analysis using imputation methods did not
change the result.
Future work: Clinical trials to investigate other pharmacological interventions (monotherapy vs.
combination therapy), physiotherapy and cognitive–behavioural therapy to treat women with chronic
pelvic pain are needed.
Trial registration: Current Controlled Trials ISRCTN77451762 and EudraCT 2014-005035-13.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a
Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be
published in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 7. See the NIHR Journals Library
website for further project information.
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Plain English summary
What was the question?
Long-standing (chronic) pelvic pain affects over 1 million women in the UK, but there is a lack of proven
treatments. If no underlying cause is found, the pain is much more difficult to treat. Gabapentin, which is
used to treat other chronic pain conditions, is being increasingly prescribed. There is no evidence to show
whether or not gabapentin is effective for chronic pelvic pain, so we conducted a clinical trial. We also
wanted to understand whether or not we could see changes in the brains of women with chronic pelvic
pain and whether or not these changes can predict response to gabapentin.
What did we do?
We involved 306 women with chronic pelvic pain, for which no cause had been found, and randomly
assigned them to take gabapentin or placebo for 16 weeks. We collected information on pain, physical
health and emotional well-being at the beginning and end of the study. Women scored their pain from
0 to 10 and sent this score by text message. We asked 45 participants to undergo a brain scan to look
at brain activity before and during treatment.
What did we find?
Gabapentin did not reduce pain and did not improve any other aspects of the women’s life compared
with placebo. Side effects were more common with gabapentin than placebo. We identified areas of
the brain that responded to gabapentin.
What does this mean?
Women with no obvious cause for their chronic pelvic pain should be made aware that gabapentin will
not relieve their pain and may give them unpleasant side effects. More research is required to see if
physiotherapy or talking therapies can help instead.
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Scientific summary
Background
Long-standing (chronic) pelvic pain affects over 1 million women in the UK. It is the reason for 20% of
gynaecological consultations and causes a 45% reduction in work productivity. The annual cost of
caring for women in the UK with chronic pelvic pain has been estimated to be £154M.
The pathogenesis of the painful symptoms experienced by women with chronic pelvic pain is poorly
understood. The painful symptoms are associated with specific pathological processes, such as endometriosis,
but up to 55% of women with chronic pelvic pain appear to have no obvious underlying pathology.
The management of chronic pelvic pain is difficult because in the absence of underlying pathology no
established gynaecological treatments are available.
Objectives of the main trial
The GaPP2 trial was designed to test the hypothesis that treatment with gabapentin has the potential
to provide a safe, effective, convenient oral treatment that alleviates pain in women with chronic pelvic
pain in the absence of any obvious pelvic pathology. We also wanted to test the hypothesis that
treatment with gabapentin has the potential to improve physical and emotional functioning.
Objectives of the mechanistic substudy
The mechanistic component of the trial had the following objectives:
l determine the presence of central nervous system changes in women with chronic pelvic pain and
no obvious underlying pathology
l determine the effect of gabapentin on central pain processing in women with chronic pelvic pain
and no underlying pathology
l determine whether or not there are baseline functional magnetic resonance imaging measures that
correlate with response to treatment
l determine whether or not there are clinical measures that correlate with response to treatment.
Design
This was a randomised, double-blind, placebo-controlled, multicentre trial with a mechanistic substudy
to explore the mechanism of action of gabapentin.
Methods
Setting
The trial was conducted in 39 sites in NHS hospital settings across the UK, recruiting between 2015
and 2019. The mechanistic substudy was conducted only at the Edinburgh Imaging Facility at the
University of Edinburgh.
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Participants
For the main trial, informed consent was sought from women (aged between 18 and 50 years) with
chronic pelvic pain and no obvious pelvic pathology at laparoscopy. For the mechanistic substudy,
Edinburgh participants who consented to the main trial were approached to undergo a functional
magnetic resonance imaging scan of the brain.
Interventions
Each participant received either gabapentin capsules at a dose of 300 mg three times per day
(increased to a maximum dose of 2700 mg) or placebo capsules. These were commenced at
randomisation and continued for a total of 16 weeks (4-week dose escalation followed by 12 weeks on
the optimal dose). Optimal dosing was determined by the participants, who were instructed to increase
their dose until they perceived adequate pain relief or intolerance to perceived side effects. Neither
the clinician nor the participant knew which group they were allocated to throughout the study.
Screening and randomisation
Participants were asked to return numerical rating pain scores weekly for 4 weeks on both the
average and the worst scales (scores range from 0 to 10, where 0 is no pain and 10 is the worst pain
imaginable). If at least three of the four pain scores were returned on both scales and at least two of
the worst pain scores were ≥ 4, then the woman was considered fully eligible for the trial and was
invited to attend a randomisation visit. Randomisation was performed online via a secure internet
facility. Women were unblinded at the end of the treatment phase after all data were collected.
Outcome measures
Primary
Dual measures of worst and average pelvic pain scores assessed weekly by a numerical rating scale at
baseline and then during the final 4 weeks of treatment (weeks 13–16 post randomisation).
Secondary
l Numerical rating score of pain: to include an examination of the proportion of women who have a
30% or 50% reduction in average and worst pain scores from baseline to the end of treatment
(pain scores ranging from 0, no pain, to 10, worst pain imaginable).
l Short Form-12 quality of life: the Short Form Health Survey provides summary information on
physical and mental health status.
l Brief Pain Inventory: a comprehensive instrument for pain assessment.
l Brief Fatigue Inventory: to measure the severity of fatigue in adults.
l General Health Questionnaire (short): to identify psychological distress.
l Work and Productivity Activity Impairment: a valid questionnaire for assessing impairments in paid
work and activities.
l Pain Catastrophizing Scale: one of the most widely used instruments for measuring catastrophic
thinking related to pain.
l Sexual Activity Questionnaire: a valid, reliable and acceptable measure for describing the sexual
functioning of women in terms of pleasure and discomfort.
l PainDETECT™: a new screening questionnaire to identify neuropathic components in patients.
l Pelvic Pain and Urinary/Frequency Patient Symptom Scale (baseline only): a questionnaire that is
predictive of treatment success.
l Number of attendances to health-care professionals for chronic pelvic pain.
l Use of concomitant medications was recorded to identify any reductions in analgesic use.
SCIENTIFIC SUMMARY
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Mechanistic substudy
Brain activity (measured by functional magnetic resonance imaging) at rest and evoked in response to
punctate stimuli.
Results
Main trial
A total of 1348 participants were approached for participation, and 414 were consented to the
initial screening phase. Of these women, 306 were randomised, 153 allocated to gabapentin and
153 allocated to placebo. Ten women withdrew from GaPP2 and one woman died. In addition,
primary outcome data were unavailable in 62 and 60 women for the average and worst pain scores,
respectively. Sensitivity analyses using a multiple imputation approach were performed to assess the
effect of missing responses.
The baseline data (age, body mass index and maternal ethnicity) of the participants were comparable
in the two groups of the trial. In weeks 13–16, the mean worst pain score was 7.1 (standard deviation 2.6)
in the gabapentin group and 7.4 (standard deviation 2.2) in the placebo group (adjusted mean difference
–0.20, 97.5% confidence interval –0.81 to 0.42; p = 0.47). The mean average pain score was 4.3 (standard
deviation 2.3) in the gabapentin group and 4.5 (standard deviation 2.2) in the placebo group (adjusted
mean difference –0.18, 97.5% confidence interval –0.71 to 0.35; p = 0.45). No significant between-group
differences were observed for any secondary outcome. A higher proportion of women experienced a
serious adverse event in the gabapentin group than in the placebo group (10/153 vs. 3/153; p = 0.04).
Dizziness, drowsiness and visual disturbances were more common in the gabapentin group.
Mechanistic substudy
A total of 83 women were consented in Edinburgh for the main trial. Of these, 45 consented to take
part in the mechanistic study and had a baseline functional magnetic resonance imaging brain scan;
25 returned for a follow-up scan between weeks 12 and 16 of treatment. Twelve women were in
the placebo group and 13 were in the gabapentin group. Whole-brain and a priori defined region of
interest analyses were performed. Group mean activation included regions known to be important in
the processing of pain. Compared with placebo, gabapentin reduced evoked activity in the anterior
cingulate cortex and the cuneus. In the gabapentin group, changes in activity in the anterior cingulate
cortex tracked with clinically meaningful improvements (Brief Pain Inventory pain interference scores);
however, this was not the case for the cuneus. Baseline evoked activity in the anterior cingulate cortex
was also a predictor of response, with those with the greatest activity having a greater improvement in
the physical component of the Short Form-12 and reduction in their PainDETECT scores.
Conclusions
Gabapentin did not reduce pain scores and did not improve other outcomes compared with placebo
over the course of 16 weeks. Serious adverse effects were significantly higher in the gabapentin group
than in the placebo group. In the mechanistic study, gabapentin exerted a clinically relevant effect on
the anterior cingulate cortex.
Women with chronic pelvic pain and no obvious pelvic pathology should be advised that gabapentin
may not alleviate their pain and may give them unpleasant side effects. No further research is
required. Questions that remain unaddressed relate to the use of other pharmacological interventions
(monotherapy vs. combination therapy), physiotherapy and cognitive–behavioural therapy for treating
women with chronic pelvic pain.
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Chapter 1 Introduction
Parts of this chapter have been reproduced from Lewis et al.1 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Clinical background
Chronic pelvic pain (CPP) is as common as asthma, migraine and back pain,2 and affects more than
1 million women in the UK.3 It is associated with significantly reduced quality of life4,5 and a 45%
reduction in work productivity, and it has been estimated that caring for women with CPP in the UK
costs £154M annually.6,7 CPP can be associated with an underlying pathology, such as endometriosis,
but in up to 55% of women no obvious cause can be identified at laparoscopy.7 Management of CPP is
difficult when no pathology is identified, as no established gynaecological treatments are available, but
careful exploration of the patient’s symptoms and history may point to non-gynaecological causes of
CPP for which some effective treatments exist.
Increasing evidence demonstrates that people suffering with chronic pain conditions show many
physiological similarities to healthy pain-free controls, no matter what/where the underlying cause of
the pain.8–11 This has led some to argue that ‘chronic pain’ should be considered as a disease in its own
right,12 and at the very least points towards the use of treatments targeting central pain mechanisms in
addition to disease-specific therapies.
Drugs targeting central pain mechanisms
There are three main classes of drugs that are used as adjunctive analgesics for both the treatment of
neuropathic pain and the treatment of conditions thought to have a central component (e.g. fibromyalgia):13,14
tricyclic antidepressants, gabapentinoids and selective serotonin and noradrenaline reuptake inhibitors.
However, much of this use is currently ‘off-licence’, as the specific indications for which each drug is
licensed varies. At the time of the design of the pilot study for this trial (GaPP1),1,15 there was an increase
in the prescription of these adjunctive analgesics for CPP in both primary and secondary care16 owing
to their effectiveness in managing other chronic pain conditions. The rate of patients newly treated
with gabapentinoids in primary care tripled from 2007 to 2017 and, by 2017, 50% of gabapentinoid
prescriptions were for an off-label indication.We also observed at the time that there was considerable
use of gabapentin for CPP (largely because of its perceived effectiveness in other chronic pain conditions).
First, with the support of the Scottish Primary Care Research Network, we surveyed a random group of
general practitioners (GPs). Of the GPs who responded to our survey, 74% said that they would consider
gabapentin as a treatment option for CPP in women. Second, with the support of the Royal College of
Obstetricians and Gynaecologists, we surveyed a random group of gynaecologists and 50% said that
they currently prescribe gabapentin for CPP, and > 90% said that they would consider gabapentin as a
treatment option for this condition. Since then, awareness and use of gabapentinoids has continued to
increase in gynaecology, with the publication of reviews in this area17 and reference within the National
Institute for Health and Care Excellence (NICE) guideline for endometriosis18 to the NICE guideline on
neuropathic pain for treatment of CPP with neuromodulators.19 This was despite the fact that there was
no good-quality evidence of efficacy in CPP specifically on which to base this practice, and the fact that
these drugs were not licensed for CPP. One randomised controlled trial (RCT)20 compared the efficacy of
gabapentin and amitriptyline for CPP in women with a range of pelvic pathologies; however, this study
was open label, there was no placebo group, the population had a mixed aetiology of pain symptoms and
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the numbers analysed were small (n = 56). Another placebo-controlled trial of 60 women from Egypt21
did show a statistically, and potentially clinically, significant difference in patient-reported pain after
12 weeks of treatment, but the variability of the patient responses was considerably lower than all
previous studies of CPP and not generalisable outside that population. The trial was not powered to
detect meaningful differences and had substantial attrition.21 Our own pilot trial (GaPP1)1 was not
powered to detect meaningful differences and experienced significant attrition. There were no studies
investigating pregabalin or duloxetine for this indication. Interestingly, there was one RCT of pregabalin
for treating CPP in men that showed no benefit of treatment over placebo after a 6-week course of
treatment.22 During the course of our trial a subsequent paper was published (albeit a retrospective
database analysis rather than a clinical trial) that reported greater benefit of gabapentin than pregabalin
for CPP in men.23 To date, to our knowledge, there remain no studies investigating duloxetine for this
indication in men or women. Given the benefit of gabapentin over amitriptyline in the one existing study
of CPP in women,20 this was the adjunctive analgesic chosen for further investigation in GaPP1 and
subsequently the full trial reported here (GaPP2).
Although there is limited evidence of the efficacy of gabapentin in CPP, there is proven benefit of the
efficacy of gabapentin in other chronic pain conditions. A systematic review showed that the number
needed to treat against placebo to be 5.8 [95% confidence interval (CI) 4.3 to 9.0] to achieve at least
50% pain-intensity reduction in painful diabetic neuropathy (829 patients); 7.5 (95% CI 5.2 to 14)
to achieve at least 50% pain-intensity reduction in postherpetic neuralgia (892 patients); and 5.4
(95% CI 2.9 to 31) to achieve at least 30% pain-intensity reduction in fibromyalgia (150 patients).16
Furthermore, gabapentin is a drug that is very well tolerated: all-cause withdrawal rates are similar
to placebo (gabapentin, 20%; placebo, 19%; n = 17 studies; n = 3063 participants).16
Recent safety concerns regarding gabapentinoids
Despite clinical trial data suggesting gabapentin to be well tolerated, there have been significant
concerns regarding the risk of both abuse and dependence associated with the use of gabapentinoids,
both their use clinically and their illicit use recreationally. There is certainly good evidence of misuse
of gabapentin in the population as a whole, and this seems to be particularly the case for individuals
with a history of substance abuse and if there is concomitant opiate or benzodiazepine use.24,25 Of
relevance to GaPP2, it does appear that men may be more vulnerable to these effects than women.26
Nonetheless, given that gabapentinoids are commonly prescribed for symptoms that are significantly
more prevalent in women (chronic pain, anxiety and climacteric symptoms), large data sets will be
required to discern with certainty whether or not a sexual dimorphism exists. However, in April 2019
(while GaPP2 was recruiting), gabapentin and pregabalin were reclassified as controlled drugs under
the Misuse of Drugs Act 197127 as class C substances, and scheduled under the Misuse of Drugs
Regulations 2001 as ‘schedule 3’.28
Recently, there has also been increased concern of the side-effect profile of gabapentinoids.29 A large,
retrospective, cohort study identified an increased risk of suicidal behaviour, unintentional overdoses,
head/body injuries and road–traffic incidents and offences with gabapentinoids. The risks were,
however, significantly higher for pregabalin than for gabapentin, and associations with adverse
outcomes were mainly seen in the 15–24 years age group. In fact, gabapentin was not associated
with an increased risk of suicidal behaviour and was associated with a decreased risk of road–traffic
incidents and offences, and violent crime. These data suggest that the risks of pregabalin, particularly
in adolescents, may have been underestimated; however, these data are reassuring for gabapentin,
except when combined with opiates or for those with a history of substance abuse.
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Potential mechanism of action of gabapentin in chronic pelvic pain
The gabapentinoids are thought to exert their analgesic effect by binding to the alpha-2/delta subunit
of voltage-gated calcium channels on primary afferent neurons, thereby reducing the release of
neurotransmitters from their central terminals.30–32 In line with the observed centrally mediated
adverse effects (somnolence, dizziness and nausea) of gabapentin, neuroimaging studies have also
demonstrated gabapentin to exert an effect on the activation of specific brain regions in both
humans33,34 and rats.35 The preclinical study35 looked at anaesthetised animals at rest and observed
reduced activation in areas of the brain known to be involved in pain perception after infusion of
gabapentin; these data were also consistent with known pharmacokinetics with respect to transport
of gabapentin across the blood–brain barrier. The human studies33,34 were both carried out on healthy
volunteers, but used an induced model of central sensitisation (capsaicin induced). They show that
gabapentin is able to reduce the abnormal brainstem activity in response to a mechanical stimulus
associated with this sensitised state,33 and that this effect could distinguish between gabapentin,
ibuprofen and placebo.34 Of relevance to the GaPP2 trial, the first study was undertaken in a cohort
of 12 men33 and the second in a mixed cohort of 25 subjects, 13 of whom were women.34 There has
been one study36 exploring the central effects of pregabalin on a female cohort of fibromyalgia patients
(n = 27). To the best of our knowledge, there are still no other studies focusing on the effects of
gabapentin in a solely female cohort of chronic pain patients, except a pilot neuroimaging analysis from
the GaPP1 study.37
Clinical research questions
1. What is the efficacy of gabapentin compared with placebo in the alleviation of pain in women with
CPP without any obvious pelvic pathology?
2. Does gabapentin, compared with placebo, significantly improve physical and emotional functioning
in women with CPP without any obvious pelvic pathology?
Mechanistic substudy research questions
1. Are there central nervous system changes in women with CPP and no underlying obvious
pelvic pathology?
2. What is the effect of gabapentin on central pain processing in women with CPP and no underlying
obvious pelvic pathology?
3. Are there any baseline functional magnetic resonance imaging (fMRI) measures that correlate to
response to treatment?
4. Are there clinical measures that correlate to response to treatment?
To address these research questions, we proposed the following:
i. to conduct a high-quality, multicentre RCT comparing gabapentin with placebo in women with CPP
without any obvious pathology
ii. to explore possible subgroup effects of gabapentin owing to the presence or absence of
dysmenorrhoea, psychological distress and hormone treatment
iii. to conduct fMRI studies on a representative subsample of trial participants to identify changes in
brain activity that are altered by gabapentin and identify potentially predictive brain activity
markers of treatment response.
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Chapter 2 Methods
This chapter reports the methods used to conduct the GaPP2 trial.
Trial design
The GaPP2 trial was a placebo-controlled, randomised, blinded, multicentre trial of gabapentin for
the management of CPP in women with no known aetiology with a nested-mechanistic fMRI brain
study (see Chapter 4). The trial had a favourable ethics opinion from Research Ethics Committee
West Midlands – Coventry and Warwickshire (Multicentre Research Ethics Committee reference
15/MW/0036).
Recruitment
The GaPP2 trial participants were recruited from gynaecology outpatient departments in 39 participating
NHS sites across the UK. The GaPP2 trial recruitment followed a two-step process (Table 1). Potential
participants were referred, with their permission, to the local research teams by their attending
clinician. All participants were told that participation in the trial was completely voluntary and that
they could withdraw at any stage in the trial. This was part of the consent process. Participants were
reassured that participation or withdrawal would not affect their normal clinical care. All women
were approached, with permission, by researchers who were trained in Good Clinical Practice and
specifically in taking consent for this trial. Potential participants were provided with a participant
information sheet and given time to consider their involvement. If participants expressed an interest,
written informed consent was sought and participants were invited to a screening visit at which
they were assessed for eligibility. For the mechanistic substudy, eligible participants in Edinburgh
only were given a separate participant information sheet and, if interested, signed a second consent form.
Eligibility criteria
Participants were assessed for eligibility by an appropriately trained doctor. The participants needed
to meet the following criteria:
l women aged between 18 and 50 years
l experiencing CPP (non-cyclical with or without dysmenorrhoea or dyspareunia) of
> 3 months duration
l having pain located within the true pelvis or between and below anterior iliac crests
l having no obvious pelvic pathology at laparoscopy (laparoscopy must have taken place at
least 2 weeks prior to consenting to participation, but no more than 36 months prior
to screening)
l using, or willing to use, effective contraception if necessary to avoid pregnancy
l able to give informed consent.
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TABLE 1 Summary of trial design
Phase Flow of participant through the trial Outcomes collected Time scale
Recruitment Women with CPP Eligibility criteria ≤ 3 years and
> 2 weeks
Laparoscopy and ultrasound: no or minimal
pathology seen
If recent laparoscopy:
information provided
before discharge
If identified from
patient referrals:
information sent to
respondent
Consent and screening
Run-in Pre randomisation NRS –4 weeks
NRS –3 weeks
NRS –2 weeks
NRS –1 week
Randomisation
(n= 300)
fMRI scan of the brain,
PROMs
0 weeks
(baseline)
Gabapentin dispensed
(n= 150)
Placebo dispensed
(n = 150)
Titration Gabapentin
commenced and
escalate dose
Placebo commenced
and escalate dose
AEs collected 1 week
2 weeks
3 weeks
4 weeks
Treatment Maximum-tolerated dose maintained 5 weeks
6 weeks
7 weeks
8 weeks
9 weeks
10 weeks
11 weeks
12 weeks
NRS 13 weeks
NRS 14 weeks
NRS 15 weeks
NRS 16 weeks
End of study fMRI brain scan,
PROMS
Unblinding
Taper Gabapentin taper down or remain on treatment AEs collected 17–20 weeks
AE, adverse event; NRS, numerical rating scale; PROM, patient-reported outcome measure.
METHODS
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Participants could not be included if any of the following criteria were applicable:
l known pelvic pathology –
¢ endometriosis (macroscopic lesions)
¢ complex or > 5 cm ovarian cyst or fibroid > 3 cm
¢ dense adhesions
l current malignancy under treatment
l current use of gabapentin or pregabalin
l taking gonadotropin-releasing hormone agonists, and unable or unwilling to stop
l surgery planned in the next 6 months
l history of significant renal impairment
l previous reaction to gabapentin
l breastfeeding
l pregnant
l planned pregnancy in the next 6 months
l pain suspected to be of gastrointestinal origin (positive Rome III Diagnostic Criteria)
l co-enrolment in another clinical trial of an investigational medicinal product
l metal implant/pacemaker/claustrophobia (fMRI mechanistic study only)
l receiving prohibited medications (e.g. pregabalin or high-dose opioids).
The final element of eligibility was a 4-week screening phase. Participants were asked to return
numerical rating scale (NRS) pain scores weekly for 4 weeks on both the average and the worst scales
(scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable). If at least three of
four pain scores were returned on both scales, and at least two of the worst pain scores were ≥ 4, the
woman was considered fully eligible for the trial and was invited to attend a randomisation visit. No
study drugs were taken during this pre-randomisation screening phase, but participants were able to
remain on any analgesics they were taking.
Randomisation method and minimisation variables
Once final eligibility was confirmed and consent obtained, women were randomised to the GaPP2 trial by
the research staff at sites using a secure online randomisation service provided by the Birmingham
Clinical Trials Unit (BCTU) (see Table 1). Participants were randomised in an equal (1 : 1) ratio to
gabapentin or placebo, and a bottle number was allocated. The bottle number was sent via e-mail to the
local principal investigator (PI), the trial pharmacist and the research nurse undertaking the randomisation.
A ’minimisation’ procedure, incorporating a random element using a computer-based algorithm, was used
to avoid chance imbalances in important prognostic variables. Strata used in the minimisation were:
l Presence or absence of dysmenorrhoea (yes, no); a pain score of ≥ 4 was considered as ‘presence of
dysmenorrhoea’ (on a NRS of 0–10).
l Psychological distress measured by the General Health Questionnaire (short) (GHQ-12) (≥ 2 on a
0–12 scale).
l Use of sex hormonal treatments (yes, no) (e.g. combined oral contraceptives, progestogens and
levonorgestrel-releasing intra-uterine system).
l Recruiting centre.
Investigation medicinal product information
The investigational medicinal product (IMP) was gabapentin in the form of an overencapsulated
capsule. Each capsule contained 300 mg of gabapentin.
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The placebo was lactose powder, which was encapsulated in the same way as the IMP to be identical in
colour, shape and weight. The treatment regime was exactly the same as in the gabapentin group. For
the gabapentin, it was assumed that given that the outer capsule disintegrates, the excipient falls away
and exposes the original gabapentin capsule. Disintegration of the original capsule and subsequent
bioavailability were not impacted by the overencapsulation.
Interventions were supplied by Sharp Clinical Services (Tredegar, UK), who procured the trial drug and
manufactured the placebo capsule, overencapsulated the IMP and placebo, and dispensed into containers
accordingly. This company had no role in the design, conduct, analysis or reporting of the trial.
A clinical trial pharmacist prepared the trial treatment bottle for dispense. Each trial treatment bottle
contained 155 capsules. This was enough to see every participant through the dose-escalation phase. Bottles
were then dispensed at each visit, depending on the optimal dose reached, up to a maximum of seven bottles.
Treatment allocations
Participants commenced the trial intervention on the day that they were randomised. They commenced
on a dose of 300 mg and increased this by 300 mg every 3 days. Doses were split into three doses
three times per day. Participants were given written instructions regarding dose escalation (Table 2).
This took place in the first 4 weeks of treatment. Optimal dosing was determined by the participants,
who were instructed to increase until they perceived adequate pain relief or intolerance to the
perceived side effects. The optimal dose was then continued for 12 weeks. At the end of the treatment
phase, the dose was reduced over a 2-week period (written instructions were provided; Table 3), unless
there was a clinical decision to continue open-label treatment.
Blinding
Participants, investigators, research nurses and other attending clinicians all remained blind to the trial
drug allocation for the duration of their participation. All participants were unblinded at the end of
the trial after all data were collected. Women who perceived a benefit from gabapentin were able to
discuss treatment continuance at their optimal dose on open-label treatment following discussion with
their direct clinical care team.
TABLE 2 Dose escalation instructions
Day in trial
Total number of capsules
per day (maximum) Dosing
Maximum daily dose
of gabapentin
1 1 One capsule at night 300 mg
2 1 One capsule at night 300 mg
3 1 One capsule at night 300 mg
4 2 One capsule twice daily 600 mg
5 2 One capsule twice daily 600 mg
6 2 One capsule twice daily 600 mg
7 3 One capsule three times daily 900 mg
8 3 One capsule three times daily 900 mg
9 3 One capsule three times daily 900 mg
10 4 One capsule twice and two capsules
at night
1200 mg
METHODS
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TABLE 3 Dose reduction instructions
Number of capsules to be taken and when
Total number of
capsules per day
(maximum)
Three capsules three times daily (morning, afternoon and night) 9
Three capsules in the morning and two capsules in the afternoon and three capsules at night 8
Two capsules in the morning and two capsules in the afternoon and three capsules at night 7
Two capsules three times daily (morning, afternoon and night) 6
Two capsules in the morning and one capsule in the afternoon and two at night 5
One capsule in the morning and one capsule in the afternoon and two at night 4
One capsule three times daily (morning, afternoon and night) 3
One capsule in the morning and one at night 2
One capsule at night for one night 1
TABLE 2 Dose escalation instructions (continued )
Day in trial
Total number of capsules
per day (maximum) Dosing
Maximum daily dose
of gabapentin
11 4 One capsule twice and two capsules
at night
1200mg
12 4 One capsule twice and two capsules
at night
1200mg
13 5 Two capsules twice and one capsule once 1500mg
14 5 Two capsules twice and one capsule once 1500mg
15 5 Two capsules twice and one capsule once 1500mg
16 6 Two capsules three times daily 1800mg
17 6 Two capsules three times daily 1800mg
18 6 Two capsules three times daily 1800mg
19 7 Two capsules twice and three capsules
at night
2100mg
20 7 Two capsules twice and three capsules
at night
2100mg
21 7 Two capsules twice and three capsules
at night
2100mg
22 8 Three capsules twice and two capsules once 2400mg
23 8 Three capsules twice and two capsules once 2400mg
24 8 Three capsules twice and two capsules once 2400mg
25 9 Three capsules three times daily 2700mg
26 9 Three capsules three times daily 2700mg
27 9 Three capsules three times daily 2700mg
28–112 Remain on maximum-tolerated dose for 12 weeks (not exceeding 2700mg or nine capsules per day).
Daily dose should be divided equally into three doses
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In case of any serious adverse event (SAE), the general recommendation was to initiate management
and care of the participant as if the woman was taking gabapentin. Cases that were considered serious,
unexpected and possibly, probably or definitely related to the trial intervention (see Vincent et al.38)
were unblinded as appropriate. In any other circumstances, investigators, research nurses and
midwives remained blind to drug allocation while the participant remained in the trial. However,
if the drug allocation was specifically requested immediately to assist the medical management of a
participant, clinicians could contact the relevant pharmacy department where code-break envelopes
were kept for each individual bottle that held the related allocation for that bottle.
Scheduled trial appointments
Trial participants completed five trial visits in total, which comprised the initial screening visit,
randomisation and three follow-up visits that were conducted at weeks 4–5 (visit 3), 8–10 (visit 4) and
16–17 (visit 5 was the end of the trial) (Box 1). If no resupply of the IMP was required, women were
able to complete visits 3 and 4 over the telephone. At each follow-up visit, adverse events (AEs), use
of rescue analgesia and any side effects were captured, and, for visit 5 only, visits to a GP and other
health-care professionals were recorded. For the mechanistic substudy, participants were asked to
attend for a fMRI scan at the time of their second visit (pre randomisation), and were then asked to
return at the time of their fifth visit (before unblinding).
BOX 1 Schedule of trial assessments
Possible recruit identified by clinician
l Pelvic pain > 3 months.
l No pathology at laparoscopy at < 36 months and > 2 weeks.
l Not on gabapentin/pregabalin.
l Not pregnant/planning pregnancy.
l Asked permission to be approached by research staff.
Approached by research staff
l GaPP2 patient information sheet.
l fMRI substudy patient information sheet (Scotland).
l Asked permission to be contacted regarding study entry.
Visit 1 (pre-trial eligibility) (week –4)
Participant
l Informed consent.
l Pre-screening.
Research team
l Eligibility.
l Contact details.
Weekly contact (weeks –4 to –1)
l NRS worst and average scores.
l Option to withdraw.
l fMRI (Scotland only) (blood sample): visit 1A.
METHODS
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Visit 2 (baseline: week 0)
Participant
l Screening.
l Randomised.
l Treatment diary.
l Questionnaires.
l Saliva sample.
Research team
l Confirm eligibility.
l Reviews SAEs.
l Option to withdraw.
Visit 3 (week 4)
Participant
l Collect medication (if required).
Research team
l Review treatment diary.
l Review AEs.
l Option to withdraw.
Visit 4 (week 10) (can be remote consultation)
Participant
l Collect medication (if required).
Research team
l Review treatment diary.
l Review AEs.
l Option to withdraw.
Weekly text message (weeks 13–16)
l NRS worst and average scores.
l Option to withdraw.
l fMRI (Scotland only) (blood sample): visit 4A.
Visit 5 (week 17)
Participant
l Questionnaires.
l Unblinding.
Research team
l Collect diary.
l Collect medication.
l Review AEs.
l Review treatment.
Taper down treatment (weeks 17–19)
l As required and remote consultations.
BOX 1 Schedule of trial assessments (continued )
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Adherence monitoring
Adherence was evaluated by two methods. First, women were asked to complete a daily treatment
diary, which documented how many capsules of IMP were taken. When women provided data for at
least 5 days in 1 week, the weekly median number of capsules taken was calculated. Second, the
participant was asked about adherence to the study medication at their final follow-up visit (visit 5).
This was asked as a categorical response with the following groups: never (0%), hardly any (1–24%),
some (25–49%), most (50–74%), almost always (75–99%) and every day (100%). Women were defined
as adherent if they reported taking ≥ 50% of their study drug at visit 5 [most (50–74%), almost always
(75–99%) or every day (100%)]. Women who were considered adherent as per this definition
constituted the per-protocol cohort.
Participant withdrawal
A participant was considered for withdrawal from the trial treatment if, in the opinion of the
investigator or the care-providing clinician or clinical team, it was medically necessary to do so.
Participants could also voluntarily withdraw from treatment at any time; however, women were
encouraged to continue follow-up after withdrawal from the trial treatment to minimise attrition bias.
Participants could voluntarily withdraw their consent to study participation at any time. If a participant
did not return for a scheduled visit, attempts were made to contact them and, where possible, review
adherence and safety data. Reasons for withdrawal were captured where possible. If a participant
explicitly withdrew consent to have any further data recorded, their decision was respected and
recorded on the electronic data capture system. All communication surrounding the withdrawal was
noted in the patient’s medical notes, and no further data were collected for that participant.
Outcomes and assessments
Primary outcome measures
We employed dual primary outcome measures of average and worst pain scores recorded on a NRS.
These were assessed and interpreted as separate outcomes. Weekly pain scores (ranging from 0,
no pain, to 10, the worst pain imaginable) were recorded, during the final 4 weeks of treatment
(weeks 13–16 post randomisation) in the form of (1) ‘average pain this week’ and (2) ‘worst pain this
week’. The average pain score was taken as the average of ‘average pain this week’ and the worst
pain score as the worst response from ‘worst pain this week’ over the 4 weeks of assessment.
Secondary outcome measures
Secondary outcomes are as follows:
l Numerical rating score of pain – to include an examination of the proportion of women who have
a 30% or 50% reduction in average and worst pain scores from baseline to the end of treatment
(pain scores ranging from 0 meaning no pain to 10 being worst pain imaginable).
l Short Form-12 (SF-12) quality of life – Short Form Health Survey provides summary information on
physical and mental health status.39
l Brief Pain Inventory (BPI) – a comprehensive instrument for pain assessment.40
l Brief Fatigue Inventory (BFI) – to measure the severity of fatigue in adults.41
l GHQ-12 – to identify psychological distress.42
l Work and Productivity Activity Impairment Questionnaire (WPAIQ) – a valid questionnaire for
assessing impairments in paid work and activities.43
l Pain Catastrophizing Scale (PCS) – one of the most widely used instruments for measuring
catastrophic thinking related to pain.44
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l Sexual Activity Questionnaire (SAQ) – a valid, reliable and acceptable measure for describing the
sexual functioning of women in terms of pleasure and discomfort.45
l PainDETECT™ – a new screening questionnaire to identify neuropathic components in patients.46
l Pelvic Pain and Urinary/Frequency Patient Symptom Scale (baseline only) – a questionnaire that is
predictive of treatment success.47
l Number of attendances to health-care professionals for CPP.
l Use of concomitant medications was recorded to identify any reductions in analgesic use.
Outcome assessment details
The schedule of outcome assessments is given in Table 4. Details of how outcomes were generated are
given in Table 5.
TABLE 4 Schedule of outcome assessments
Phase
Screening
phase
Baseline,
randomisation
and treatment
dispensed Titration Treatment
End of
study and
unblinding Taper
Duration (weeks) –4 to –1 0 1–4 5–12 13–16 17 17–19
Weekly worst
and average
NRS
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Saliva sample ✓
SF12 ✓ ✓
BPI ✓ ✓
PCS ✓ ✓
SAQ ✓ ✓
BFI ✓ ✓
GHQ-12 ✓ ✓
WPAIQ ✓ ✓
PainDETECT ✓ ✓
PUF patient
symptom scale
✓
Adverse events ✓ ✓ ✓ ✓ ✓
Permitted/
concomitant
medication
✓ ✓ ✓ ✓ ✓
Adherence or
discontinuation
✓ ✓ ✓ ✓
fMRI substudyb
fMRI brain
scan
✓ ✓a
Blood sample ✓ ✓
PUF, Pelvic Pain and Urinary/Frequency.
a A second fMRI scan should take place a minimum of 8 weeks following randomisation.
b 50 Scottish participants; fMRI scan carried out in Edinburgh.
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Relevant trial data were transcribed directly into a secure web-based database. All personal information
was treated as strictly confidential. Source data comprised the case report forms, questionnaires and
hospital notes. Women were encouraged to report AEs occurring between clinic visits or visits to
non-participating hospitals to the research nurse. Self-reports were verified against clinical notes. Pain
scores were reported by women via text messages, which were imported directly into the trial database
using a third-party company called ‘Textlocal’ (Chester, UK). There were validation methods built into
this system to ensure data consistency and quality. Any text message sent by women that did not
contain only a numerical digit between 0 and 10 generated an e-mail to the GaPP2 trial mailbox for
interpretation or chasing up. All worst/average pain scores were checked on entry to ensure that they
were the right way round (logically worst scores should be higher than average scores). Furthermore, any
scores that had been inputted into the database manually following collection of the pain score over the
telephone could not be overwritten by a subsequent text message.
Adverse events and serious adverse events
All AEs, from consent to the end of treatment (including a dose reduction if required) and whether
observed directly or reported by the patient, were collected and recorded. Commonly known side
effects of gabapentin were not reported as AEs but were captured directly into the database at each
visit. Trial participants were asked about the occurrence of AEs and SAEs at each study visit. All SAEs
were e-mailed or faxed to the sponsor’s office within 24 hours of the research staff becoming aware
of the event. The local PI (or other nominated clinician) had to assign seriousness, severity, causality
and expectedness (if deemed related) to the SAE before reporting. SAEs categorised by the local
investigator as both suspected to be related to the trial drug and unexpected were classified as
suspected unexpected serious adverse reactions (SUSARs), and were subject to expedited reporting.
In the case of any SAEs, management and care of the participant was initiated as if they were
taking gabapentin. The attending clinician and local PI were not made aware of the actual trial
drug allocation.
Pregnancy reporting
Any participants who became pregnant while on treatment were withdrawn from treatment, and all
pregnancies were followed up until delivery.
TABLE 5 Details of outcome assessments
Outcome assessed Time point Method Reported by
Weekly worst and average
NRS pain scores
Weeks 13–16 Text-messaging service Study participant
Quality-of-life questionnaires Visit 5 Completed on paper forms Study participant
Adverse events Visits 3–5 Clinical assessment of participant at
follow-up visit and medical records
Research nurse/doctor
Concomitant medication Visits 3–5 Clinical assessment of participant at
follow-up visit and medical records
Research nurse/doctor
Adherence or discontinuation Throughout the
treatment period
(weeks 1–17)
Treatment diaries and clinical follow-up
at visit 5
Study participant and
research nurse/doctor
METHODS
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Statistical considerations
Sample size
The planned sample size of 240 women was estimated to provide 90% power to detect a minimally
important clinical difference in NRS pain score of 1 point on a 0–10 scale,48 assuming a standard
deviation (SD) of 2.5 (GaPP1), which is equivalent to a standardised difference of 0.4.1 To account for
any increase in the risk of type-I error that may be associated with having dual outcome measures, a
Bonferroni correction was applied (a two-sided alpha level of 0.025 was used). We planned to include
300 women in the trial to account for up to 20% loss to follow-up.
Statistical analysis
A comprehensive statistical analysis plan (SAP) was drawn up prior to any analysis and was provided to
the independent Data Monitoring Committee (DMC) and Trial Steering Committee (TSC) for review.
In summary, categorical baseline data were summarised with frequencies and percentages. Normally-
distributed continuous variables were summarised with means and standard deviations; otherwise,
medians and interquartile ranges (IQRs) were presented. In the first instance, participants were
analysed in the treatment group to which they were randomised (intention to treat), irrespective of
adherence with the treatment protocol. All estimates of differences between groups were presented
with two-sided CIs.
For the primary outcome (average and worst pain scores), means and standard deviations were reported
alongside adjusted mean differences (with 97.5% CIs) that were estimated using a linear-regression model
adjusting for baseline score and the minimisation parameters (presence of dysmenorrhoea, psychological
distress defined by the GHQ, current use of hormonal contraceptive and recruiting hospital). Statistical
significance of the treatment group parameter was determined from the p-value generated by the model.
A Bonferroni correction was applied for multiplicity (differences considered statistically significant at
a 2.5% level). A further analysis of pain scores was examined using a repeated-measures (multilevel)
model adjusting for the minimisation parameters. All assessment times were included in the model
(weeks 13–16 pain scores), with baseline score included as a covariate in the model. Time was included
as a continuous variable in the model. Time-by-treatment effects were explored by including the
corresponding parameter in the model; if significant (p < 0.025), a constant treatment effect was not
assumed and estimates of effect size (and 97.5% CI) were generated at each time point (weeks 13–16).
A general ‘unstructured’ covariance structure was assumed.
For continuous secondary outcome measures [SF-12, BPI, BFI, GHQ-12, WPAIQ, PCS, SAQ and
PainDETECT], means and standard deviations were reported alongside adjusted mean differences
(with 99% CIs) that were estimated using a linear-regression model adjusting for baseline score and
the minimisation parameters. Binary outcomes (≥ 30% or 50% reduction in pain NRS pain scores) were
summarised using frequencies and percentages. A log-binomial model was used to generate adjusted
relative risks (and 99% CIs), adjusting for baseline score and the minimisation parameters. The number
of attendances to health-care professionals for CPP and the use of concomitant medications were
summarised descriptively only. Categorical data were summarised by frequencies and percentages.
Continuous data were summarised by the number of responses, mean and SD if they were deemed to
be normally distributed, and the number of responses, median and IQR if data appeared skewed.
Formal statistical testing was not applied.
Sensitivity analysis was performed on the dual primary outcomes only. Every attempt was made to
collect follow-up data from all participants. In particular, participants continued to be followed up even
after protocol treatment violation where possible. Patients who returned zero or one NRS pain score
were not included in the primary analysis; however, they were included in a sensitivity analysis using a
multiple imputation approach. Missing responses were simulated using a Markov chain Monte Carlo
method that assumes an arbitrary missing data pattern and a multivariate normal distribution.
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Variables, including treatment group and the three subgroup variables (listed below), were included in
the model and were used to generate 20 simulated data sets. An analysis was then performed (as per
the primary analysis) on each set, with the results combined using Rubin’s rules to obtain a single set
of results (treatment effect estimate and CIs). Further sensitivity analyses were conducted to assess
the effect of adherence; this was limited to the per-protocol cohort, as defined above, and an analysis
was carried out to assess the effect of time between screening and randomisation.
Pre-planned subgroup analyses (limited to the dual primary outcome measures only) were completed for
the following: (1) presence or absence of dysmenorrhoea (yes/no), (2) psychological distress measured by
the GHQ-12 (0–1, 2–12) and (3) current use of hormonal contraceptives (e.g. combined oral contraceptives,
progestogens and levonorgestrel intra-uterine system) (yes/no). The effects of these subgroups were
examined by adding the subgroup by treatment-group interaction parameters to the linear-regression
model; a chi-squared test was used to test the statistical significance of this parameter.
Interim analyses of effectiveness and safety end points were performed on behalf of the DMC
(see Acknowledgements) on an approximately annual basis during the period of recruitment. These
analyses were performed using the Haybittle–Peto principle;49 therefore, no adjustment was made in
the final p-values to determine significance.
Trial oversight
Study oversight was provided by a TSC that was chaired initially by Dr Jim Thornton (University of
Nottingham) and then Dr Patrick Chien (NHS Tayside), and a DMC that was chaired by Professor
Mary Ann Lumsden (University of Glasgow).
The TSC provided independent supervision for the trial, and provided advice to the chief investigator
and co-investigators on all aspects of the trial throughout the study. The DMC adopted the
DAMOCLES charter50 to define its terms of reference and operation in relation to oversight of the
GaPP2 trial.
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Chapter 3 Results of the clinical trial
This chapter reports the results of the main RCT.
Recruitment
Recruitment took place over 39 months in 39 UK NHS hospitals from November 2015 to January
2019. The contribution from each site can been seen in Table 6.
Screening of participants commenced in November 2015, and the last participant was randomised in
March 2019. The complete flow of participants through the GaPP2 trial is shown in the Consolidated
Standards of Reporting Trials (CONSORT) diagram in Figure 1. Initially, 1348 individuals were approached
for participation, of whom 414 were initially considered eligible based on clinical criteria. Of these
women, 306 women were randomised, 76 did not return for randomisation for various reasons, 20 were
ineligible because they did not return sufficient pain scores and 12 were found to be ineligible following
collection of pain scores. A total of 153 participants were assigned to the gabapentin group and 153 to
the placebo group. Ten women withdrew from the GaPP2 trial and one woman died. In addition, primary
outcome data were unavailable for 51 and 49 women for the average and worst pain scores, respectively
(across both groups) (see Figure 1). Reasons for trial withdrawal are provided in Table 7.
Pregnancy
Of the 306 randomised women, four became pregnant during follow-up in the GaPP2 trial. Of these
women, two withdrew from treatment and any further follow-up once pregnancy was known, one
withdrew only from treatment once pregnancy was known and one had withdrawn from treatment
prior to knowing she was pregnant. All babies were delivered healthy, with no reported abnormalities.
Participant characteristics
The women had a mean age of 30 years and the majority were of white ethnicity. The minimised
randomisation ensured balance between groups in terms of the proportion with a dysmenorrhoea pain
score of ≥ 4 out of 10 (65% in both groups), current use of sex hormones (65%) and GHQ-12 questionnaire
score (mean score of 4.7). The groups were also well balanced in all other baseline characteristics (Table 8).
Adherence to treatment
Of those participants with available adherence data, 101 out of 112 (90%) women in the gabapentin
group were considered adherent, compared with 101 out of 109 (93%) women in the placebo group.
A detailed breakdown of the extent of self-reported adherence to the study drug is shown in Table 9.
From the participants’ study drug diaries, the overall median number of capsules taken daily per week
was calculated for each week by trial group and is presented in Figure 2. The median number of capsules
taken during the dose-escalation phase was similar between the trial groups; thereafter, the gabapentin
group generally took one capsule more than the placebo group throughout the treatment period. The
median maximum-tolerated dose was 2100 mg (or placebo equivalent) for both groups at week 4;
however, this reached 2700 mg (the maximum permitted dose) in later weeks for some women.
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TABLE 6 Recruitment by centre
City/town Centre
Number of participants
randomised
Edinburgh Royal Infirmary of Edinburgh 60
Aberdeen Aberdeen Maternity Hospital 27
Glasgow Queen Elizabeth University Hospital 22
Southampton Princess Anne Hospital 18
South Tees The James Cook University Hospital 17
Milton Keynes Milton Keynes University Hospital 13
Burnley Burnley General Hospital 13
Kilmarnock Crosshouse Hospital 11
Chester Countess of Chester Hospital 10
Yeovil Yeovil District Hospital 9
East Kilbride Hairmyres Hospital 9
Liverpool Liverpool Women’s Hospital 9
Sunderland Sunderland Royal Hospital 9
Kirkcaldy Victoria Hospital 8
North Tees University Hospital of North Tees 8
Telford Princess Royal Hospital 8
Birmingham Birmingham Women’s Hospital 7
Rotherham Rotherham General Hospital 6
Crewe Leighton Hospital 5
Birmingham Birmingham Heartlands Hospital 5
Newcastle The Royal Victoria Infirmary 5
Walsall Walsall Manor Hospital 4
Glamorgan Royal Glamorgan Hospital 4
Oxford John Radcliffe Hospital 3
Aylesbury Stoke Mandeville Hospital 3
South Tyneside South Tyneside District General Hospital 2
London West Middlesex University Hospital 2
Manchester St Mary’s Hospital 2
London The Royal London Hospital 2
Peterborough Peterborough District Hospital 1
Worcester Worcestershire Royal Hospital 1
Inverness Raigmore Hospital 1
Darlington Darlington Memorial Hospital 1
Wrexham Wrexham Maelor Hospital 1
Chelsea and Westminster, Poole General Hospital, Hartlepool General Hospital, University College London Hospital
and University Hospital Birmingham were open to recruitment but did not randomise any participants to GaPP2.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Were approached for participation
(n = 1348)
 Consented to run-in phase
(n = 414)
Returned ≥ 3 NRS pain scores (both pain scales)
(n = 394)
Underwent randomisation
(n = 306)
Assigned to receive gabapentin
(n = 153)
• Withdrew consent,a n = 8
• Died (unrelated), n = 1
• Had data available for analysis of primary
    outcome for average pain scores, n = 123
• Had missing data imputed, n = 30
• Had data available for analysis of primary
    outcome for worst pain scores, n = 124
• Had missing data imputed, n = 29
• Considered adherent (90%), n = 101
• Considered non-adherent (10%), n = 11
• With insuff icient adherence data, n = 32
Assigned to receive placebo
(n = 153)
• Withdrew consent,a n = 2
• Not randomised, n = 76
• Were ineligible (< 2 worst pain scores ≥ 4), n = 12
Returned < 3 pain scores on either scale
(n = 20)
• Had data available for analysis of primary
    outcome for average pain scores, n = 121
• Had missing data imputed, n = 32
• Had data available for analysis of primary
    outcome for worst pain scores, n = 122
• Had missing data imputed, n = 31
• Considered adherent (90%), n = 101
• Considered non-adherent (10%), n = 8
• With insuff icient adherence data, n = 42
• Failed Rome III criteria, n = 1
• Current/previous gabapentin use, n = 14
• Cyclical pain, n = 4
• Laparoscopy took place > 3 years prior, n = 4
• Mental health concerns, n = 5
• Were pregnant/wish to conceive, n = 15
• Other medical conditions excluding, n = 12
• No longer in pain following laparoscopy, n = 28
• Previously participated in GaPP pilot, n = 1
• Wished to try other treatments, n = 2
• Provided no reason, n = 85
• Were not interested, n = 486
• Were uncontactable following approach, n = 261
• Other reasons, n = 16
Were not eligible
(n = 171)
FIGURE 1 The CONSORT diagram of the flow of participants through the GaPP2 trial. a, Withdrawn consent for any
further follow-up from the point of withdrawal.
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TABLE 7 Withdrawals and deaths in the GaPP2 trial
Type of attrition
Trial group
Gabapentin (N= 153) Placebo (N= 153)
Withdrawals,a n (%) 8 (5) 2 (1)
Reason for withdrawal (n)
Pregnancy 1 1
Withdrew consent owing to SAE 1 –
Woman feeling discomfort owing to urinary tract infection 1 –
Increased working hours and family commitments 1 –
Does not want further involvement 1 –
No reason provided 3 1
Deaths, n (%) 1 (1) 0 (–)
Cause of death,b (n)
Influenza/pneumonia 1 –
a Withdrawn consent for any further follow-up from the point of withdrawal.
b The death was unrelated to trial treatment; see Table 18 and Box 2 for further details.
TABLE 8 Demographic and baseline characteristics of the participants
Characteristic
Trial group
Gabapentin (N= 153) Placebo (N= 153)
Age (years), mean (SD); n 30.5 (7.7); 153 30.1 (8.6); 153
Dysmenorrhoea,a,b n (%) 100 (65) 100 (65)
GHQ-12 score for anxiety and depression,a,c n (%) 38 (25) 38 (25)
GHQ-12 total score,c mean (SD); n 4.6 (3.7); 153 4.7 (3.7); 153
Current use of sex hormones,a n (%) 99 (65) 99 (65)
Patch 2 (2) 0 (–)
Combined oral contraceptive pill 26 (26) 21 (21)
Progesterone-only pill 19 (19) 16 (16)
LNG IUS 38 (38) 45 (45)
Implant 12 (12) 12 (12)
Injection 5 (5) 8 (8)
Ethnicity, n (%)
White 150 (98) 148 (97)
Black (Caribbean/African/other) 1 (1) 0 (–)
Asian (Indian/Pakistani/Bangladeshi/other) 2 (1) 4 (2)
Mixed (Caribbean/African/Asian/other) 0 (–) 1 (1)
BMI (kg/m2), mean (SD); n 27.1 (5.7); 151 27.8 (5.9); 150
Education,d n (%)
Primary 4 (3) 5 (3)
Secondary 47 (31) 46 (31)
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TABLE 8 Demographic and baseline characteristics of the participants (continued )
Characteristic
Trial group
Gabapentin (N= 153) Placebo (N= 153)
Tertiary 101 (66) 101 (66)
Missing 1 1
Menstruating, n (%) 109 (71) 108 (71)
Pain score during periods,b mean (SD); n 7.7 (1.6); 103 7.6 (1.7); 103
PUF Patient Symptom Scale symptom score,e mean (SD); n 9.7 (4.1); 153 10.0 (4.5); 148
PUF Patient Symptom Scale bother score,e mean (SD); n 5.3 (2.6); 153 5.4 (2.8); 150
PUF Patient Symptom Scale total score,e mean (SD); n 15.0 (6.3); 153 15.5 (7.0); 147
Rescue medications,f n (%) 114 (75) 112 (73)
NSAIDs 62 (54) 66 (59)
Opiates 78 (68) 68 (61)
Other 61 (54) 58 (52)
Neuropathic pain,g n (%) 25 (16) 26 (17)
Missing 1 4
BMI, body mass index; LNG IUS, levonorgestrel-releasing intra-uterine system; NSAID, non-steroidal anti-inflammatory
drug; PUF, Pelvic Pain and Urinary/Frequency.
a Minimisation variable.
b Dysmenorrhoea is defined as a pain score during periods of ≥ 4. Pain scores range from 0 to 10, where 0 is no pain
and 10 is the worst pain imaginable.
c GHQ-12 scores range from 0 to 12, where higher scores represent higher levels of mental distress. A score of 0 or
1 meets the definition of anxiety and depression.
d Education unknown (gabapentin, n = 1; placebo, n= 1).
e Pelvic Pain and Urinary/Frequency Patient Symptom Scale symptom scores range from 0 to 23, bother scores range
from 0 to 12 and total scores range from 0 to 35, where low scores indicate better outcomes and high scores
indicate worse outcomes.
f Rescue medication includes NSAIDs, opiates and other. Other includes paracetamol.
g Neuropathic pain defined as a PainDETECT score of > 19.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
TABLE 9 Adherence
Adherencea
Trial group, n (%)
Gabapentin (N= 112) Placebo (N= 109)
Never (0%) 0 (–) 2 (2)
Hardly any (1–24%) 7 (6) 1 (1)
Some (25–49%) 4 (4) 5 (5)
Most (50–74%) 10 (9) 10 (9)
Almost always (75–99%) 36 (32) 34 (31)
Every day (100%) 55 (49) 57 (52)
a How frequently women reported taking their study drug.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Primary outcome
There were no significant between-group differences in both the worst and the average NRS pain
scores. The mean worst NRS pain score was 7.1 (SD 2.6) in the gabapentin group and 7.4 (SD 2.2) in
the placebo group (adjusted mean difference –0.20, 97.5% CI –0.81 to 0.42; p = 0.47). The mean
average NRS pain score was 4.3 (SD 2.3) in the gabapentin group and 4.5 (SD 2.2) in the placebo group
(adjusted mean difference –0.18, 97.5% CI –0.71 to 0.35; p = 0.45) (Table 10 and Figure 3).
Sensitivity analyses
In the per-protocol analysis of the primary outcome comparison, including only the 101 women defined
as adherent to taking the study drug in each trial group, the mean differences for worst and average
pain changed only marginally. Similarly, when multiple imputation was used to estimate missing
outcome data, the point estimate and CIs were almost identical to the intention-to-treat analysis of
available data. Finally, when the interval between the end of screening and randomisation, when the
study drug was commenced, was taken into account in the analysis model, there was no impact on the
mean difference for either pain score. These sensitivity analyses are shown in Table 11.
A subgroup analysis was carried out for the three prespecified variables used in the minimisation
algorithm, namely the presence of dysmenorrhoea, the baseline use of sex hormones and the GHQ-12
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FIGURE 2 Median dose taken daily at each assessment week by trial group. Reproduced with permission from
Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
TABLE 10 Dual primary outcome measures
Baseline End of studya
Mean differenceb
(97.5% CI); p-value
Gabapentin
group
Placebo
group
Gabapentin
group
Placebo
group
Worst NRS pain score,
mean (SD); n
8.4 (1.3); 153 8.6 (1.2); 153 7.1 (2.6); 124 7.4 (2.2); 122 –0.20 (–0.81 to 0.42); 0.47
Average NRS pain
score, mean (SD); n
5.5 (1.7); 153 5.5 (1.7); 153 4.3 (2.3); 123 4.5 (2.2); 121 –0.18 (–0.71 to 0.35); 0.45
a Worst and average NRS pain scores measured at weeks 13–16 post randomisation.
b Adjusted for baseline score and minimisation variables. Values of < 0 favour gabapentin. The threshold for statistical
significance is α = 0.025 owing to Bonferroni correction.
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score defining depression or anxiety. There was no evidence of varying effect in the three prespecified
subgroup analyses. The mean scores for worst and average pain in each subgroup are shown in Table 12.
Further analysis of pain scores, examined using a repeated-measures model, demonstrated a constant
treatment effect across time points for both worst and average scores. The mean scores for worst and
average pain at each time point are shown in Table 13.
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FIGURE 3 Primary outcome plot of worst and average NRS scores. Reproduced with permission from Horne et al.51
© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
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TABLE 11 Sensitivity analyses of the primary outcome
Primary outcome
Baseline End of studya
Gabapentin
group
Placebo
group
Gabapentin
group
Placebo
group
Mean differenceb
(97.5% CI)
Worst NRS pain scores,c mean (SD); n
Per-protocol analysisd 8.5 (1.1); 101 8.6 (1.2); 101 7.3 (2.3); 98 7.5 (2.2); 97 –0.14 (–0.81 to 0.53)
Multiple imputation for
missing data
– – – – –0.19 (–0.72 to 0.33)
Effect of time between
screening and randomisation
8.4 (1.3); 153 8.6 (1.2); 153 7.1 (2.6); 124 7.4 (2.2); 122 –0.20 (–0.82 to 0.42)
Average NRS pain scores,c mean (SD); n
Per-protocol analysisd 5.6 (1.6); 101 5.4 (1.7); 101 4.4 (2.0); 98 4.5 (2.1); 97 –0.23 (–0.81 to 0.35)
Multiple imputation for
missing data
– – – – –0.21 (–0.66 to 0.24)
Effect of time between
screening and randomisation
5.5 (1.7); 153 5.5 (1.7); 153 4.3 (2.3); 123 4.5 (2.2); 121 –0.18 (–0.71 to 0.35)
a Worst and average NRS pain scores measured at weeks 13–16 post randomisation.
b Adjusted for baseline score and minimisation variables (including time between screening and randomisation, for the
effect of time between screening and randomisation sensitivity analysis only). Values of < 0 favour gabapentin.
c Pain scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.
d The per-protocol cohort includes only those adherent with treatment allocation (gabapentin, n= 101; placebo, n= 101).
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 12 Subgroup analysis of the primary outcome
Primary outcome
Trial group
Interaction p-valueGabapentin Placebo
Worst NRS pain scores,a mean (SD); n
Dysmenorrhoea
Yes 7.2 (2.3); 79 7.4 (2.3); 78 0.7
No 6.8 (2.9); 45 7.3 (2.2); 44
GHQ-12 score
0–1 6.5 (2.4); 35 6.6 (2.2); 33 0.4
2–12 7.3 (2.6); 89 7.6 (2.2); 89
Use of sex hormones
Yes 7.2 (2.5); 81 7.1 (2.3); 81 0.1
No 6.8 (2.7); 43 8.0 (2.0); 41
Average NRS pain scores,a mean (SD); n
Dysmenorrhoea
Yes 4.5 (2.1); 79 4.4 (2.2); 77 0.3
No 3.9 (2.5); 44 4.6 (2.2); 44
GHQ-12 score
0–1 3.8 (2.2); 35 3.6 (2.2); 33 0.1
2–12 4.5 (2.3); 88 4.8 (2.1); 88
Use of sex hormones
Yes 4.5 (2.3); 81 4.3 (2.1); 81 0.3
No 3.9 (2.1); 42 4.8 (2.3); 40
a Pain scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
TABLE 13 Repeated-measures analysis
Primary outcome
Trial group
Interaction
p-value
Mean differencea
(97.5% CI)Gabapentin Placebo
Worst NRS pain scores,b mean (SD); n
Week 13 6.0 (2.7); 123 6.4 (2.5); 115 0.8 –0.29 (–0.87 to 0.29)
Week 14 5.9 (2.9); 119 6.2 (2.6); 118
Week 15 5.8 (2.8); 118 6.3 (2.4); 118
Week 16 5.8 (2.6); 116 6.2 (2.7); 118
Average NRS pain scores,b mean (SD); n
Week 13 4.5 (2.5); 122 4.7 (2.4); 114 0.8 –0.11 (–0.62 to 0.41)
Week 14 4.3 (2.5); 118 4.4 (2.5); 115
Week 15 4.4 (2.5); 118 4.5 (2.3); 118
Week 16 4.4 (2.4); 115 4.4 (2.4); 117
a Adjusted for baseline score and minimisation variables. Values of < 0 favour gabapentin.
b Pain scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Secondary outcome results
The proportion of women who reported a decrease in their pain score by at least 30% or 50% between
baseline and 13–16 weeks post randomisation was calculated, and the proportions for each group
compared. There were no differences in the proportion of participants achieving either percentage
reduction (at least 30% or 50%) for both worst and average pain scores between the groups, as shown
in Table 14.
The patient-reported outcomes were completed at the end of the treatment phase (weeks 16–17). No
significant differences were noted in any patient-reported secondary outcomes. Summary scores and
point estimates are provided in Table 15.
TABLE 14 Reduction in NRS pain scores from baseline
Secondary outcome
Trial group
Risk ratioa (99% CI)Gabapentin Placebo
Reduction in NRS score from baseline (≥ 30%), n/N (%)
Worst NRS pain score 30/124 (24) 21/122 (17) 1.38 (0.72 to 2.64)
Average NRS pain score 44/123 (36) 37/121 (31) 1.12 (0.70 to 1.80)
Reduction in NRS score from baseline (≥ 50%), n/N (%)
Worst NRS pain score 19/124 (15) 10/122 (8) 1.84 (0.71 to 4.75)
Average NRS pain score 27/123 (22) 19/121 (16) 1.36 (0.68 to 2.72)
a Adjusted for baseline score and minimisation variables. Values of > 1 favour gabapentin.
TABLE 15 Patient-reported outcomes
Patient-reported
questionnaires
Baseline, mean (SD); n End of study,a mean (SD); n
Mean difference
(99% CI)
Gabapentin
group Placebo group
Gabapentin
group Placebo group
SF-12 mental
component score
40.3 (10.8); 153 39.5 (11.3); 149 41.3 (10.6); 111 42.5 (11.1); 110 –1.11b (–4.60 to 2.39)
SF-12 physical
component score
39.0 (9.2); 153 40.1 (9.4); 149 43.8 (10.6); 111 44.6 (10.1); 110 0.49b (–2.27 to 3.24)
BPI pain
interference
score
4.9 (2.6); 152 5.0 (2.6); 152 3.6 (2.8); 111 3.6 (2.8); 112 –0.04c (–0.84 to 0.77)
BFI global fatigue
score
5.3 (2.4); 153 5.1 (2.3); 152 4.2 (2.5); 111 4.0 (2.7); 112 0.12c (–0.65 to 0.89)
GHQ-12 total
score
4.6 (3.7); 153 4.7 (3.7); 153 3.8 (3.9); 111 3.0 (3.5); 111 0.72c (–0.49 to 1.94)
WPAIQ activity
impairment score
53.4 (25.1); 153 52.1 (25.4); 151 39.3 (29.0); 110 38.6 (29.6); 111 –0.77c (–9.66 to 8.12)
WPAIQ
absenteeism
scored
10.9 (23.2); 117 12.0 (25.6); 121 10.8 (23.5); 83 4.9 (15.1); 89 5.32c (–2.06 to 12.71)
continued
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Women in the gabapentin group reported that they were taking fewer painkillers; however, these
differences were marginal and not statistically examined (Table 16).
No differences were noted in the number of visits to health-care professionals for CPP between the
gabapentin and the placebo groups (Table 17).
TABLE 15 Patient-reported outcomes (continued )
Patient-reported
questionnaires
Baseline, mean (SD); n End of study,a mean (SD); n
Mean difference
(99% CI)
Gabapentin
group Placebo group
Gabapentin
group Placebo group
WPAIQ
presenteesism
scoree
47.1 (26.2); 109 46.5 (26.7); 104 36.4 (28.4); 72 38.0 (29.6); 79 –1.89c (–14.43 to 10.65)
WPAIQ work
productivity loss
scoree
49.7 (27.9); 109 49.2 (28.2); 103 39.9 (31.1); 72 39.2 (30.7); 79 –0.43c (–13.73 to 12.87)
PCS total score 27.4 (12.9); 153 27.2 (13.0); 152 20.8 (14.6); 111 19.7 (12.5); 111 0.48c (–3.24 to 4.20)
SAQ pleasure
scoref
10.2 (4.1); 117 9.7 (4.8); 101 10.8 (4.5); 83 10.9 (4.1); 69 –0.14b (–1.84 to 1.56)
SAQ discomfort
scoref
2.9 (1.6); 117 3.1 (1.8); 100 3.6 (1.9); 84 3.3 (2.0); 68 0.17b (–0.55 to 0.90)
SAQ habit scoref 0.8 (0.6); 118 0.6 (0.6); 101 1.1 (0.8); 83 0.9 (0.7); 69 0.19b (–0.15 to 0.53)
PainDETECT
total score
13.6 (6.9); 152 13.3 (6.5); 149 12.4 (6.8); 111 10.9 (6.7); 107 1.19c (–0.74 to 3.12)
a Patient-reported questionnaires collected weeks 16–17 post randomisation.
b Mean difference (99% CI), adjusted for baseline score and minimisation variables. Values of > 0 favour gabapentin.
c Mean difference (99% CI), adjusted for baseline score and minimisation variables. Values of < 0 favour gabapentin.
d In women who are currently employed (baseline: gabapentin, n = 117, placebo, n= 122; week 16: gabapentin, n= 83,
placebo, n= 90).
e In women who are currently employed and working hours in the last 7 days > 0 (baseline: gabapentin, n= 109,
placebo, n= 104; week 16: gabapentin, n= 73, placebo, n = 79).
f In women who are currently sexually active (baseline: gabapentin, n = 123, placebo, n= 105; week 16: gabapentin,
n= 87, placebo, n = 74).
Note
Worst and average NRS, BPI and BFI scores range from 0 to 10. SF-12 and WPAIQ scores range from 0 to 100. GHQ-12
scores range from 0 to 12. PCS scores range from 0 to 52. SAQ pleasure scores range from 0 to 18. SAQ discomfort
scores range from 0 to 6. SAQ habit scores range from 0 to 3. PainDETECT scores range from –1 to 38.
TABLE 16 Summary of use of painkillers
Use of painkillers
since taking study
medication
Weeks 4–5, n (%) Weeks 8–10, n (%) Weeks 16–17,a n (%)
Gabapentin
group
(N= 118)
Placebo
group
(N= 121)
Gabapentin
group
(N= 111)
Placebo
group
(N= 108)
Gabapentin
group
(N= 103)
Placebo
group
(N= 101)
Less 65 (55) 61 (50) 57 (51) 52 (48) 52 (50) 42 (42)
Same 42 (36) 46 (38) 38 (34) 42 (39) 40 (39) 45 (44)
More 11 (9) 14 (12) 16 (15) 14 (13) 11 (11) 14 (14)
a Weeks 16–17 are the end-of-study assessment.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 17 Summary of the number of visits to health-care professionals
Number of health-care visits for CPP
Baselinea End of studyb
Gabapentin group Placebo group Gabapentin group Placebo group
GP, n (%)
Total, N 152 152 111 109
Zero 103 (68) 118 (78) 62 (56) 62 (57)
One 28 (18) 16 (10) 16 (14) 21 (19)
Two 12 (8) 10 (7) 16 (14) 11 (10)
Three or more 9 (6) 8 (5) 17 (16) 15 (14)
Hospital outpatients, n (%)
Total, N 152 152 111 109
Zero 139 (91) 126 (83) 89 (80) 83 (76)
One 10 (7) 22 (14) 16 (14) 20 (18)
Two 2 (1) 3 (2) 2 (2) 4 (4)
Three or more 1 (1) 1 (1) 4 (4) 2 (2)
Practice nurse, n (%)
Total, N 152 152 110 109
Zero 142 (93) 146 (96) 99 (90) 103 (94)
One 7 (5) 6 (4) 8 (7) 3 (3)
Two 1 (1) 0 (–) 1 (1) 1 (1)
Three or more 2 (1) 0 (–) 2 (2) 2 (2)
Physiotherapist, n (%)
Total, N 152 152 110 109
Zero 147 (97) 151 (99) 107 (97) 105 (96)
One 5 (3) 1 (1) 1 (1) 0 (–)
Two 0 (–) 0 (–) 1 (1) 1 (1)
Three or more 0 (–) 0 (–) 1 (1) 3 (3)
Other,c n (%)
Total, N 151 152 110 109
Zero 141 (93) 143 (94) 99 (90) 97 (89)
One 5 (4) 5 (4) 6 (5) 5 (4)
Two 2 (1) 2 (1) 2 (2) 3 (3)
Three or more 3 (2) 2 (1) 3 (3) 4 (4)
a Baseline: in month prior to randomisation.
b End of study (weeks 16–17): since taking trial medication.
c Includes alternative therapist, accident and emergency, occupational health, out-of-hour’s doctor, health
psychologist, pain specialist, massage therapist, research nurse, research midwife, hospital, dentist, paramedic,
magnetic resonance imaging, eye hospital and counsellor for cognitive–behavioural therapy.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Adverse events
A higher proportion of women experienced a SAE in the gabapentin group (10/153, 7%) than in the
placebo group (3/153, 2%) (p= 0.04) (Table 18). One participant, who was in the gabapentin group, died
of a complication of pneumonia that was exacerbated by other comorbidities (type 2 diabetes and obesity),
but this was not considered to be related to study participation. Dizziness and tiredness were the most
frequently reported side effects of the study treatment, but a substantial proportion of women reported
drowsiness and changes in mood and urinary patterns. Dizziness, drowsiness and visual disturbances were
significantly more common in the gabapentin group than in the placebo group (see Table 18).
TABLE 18 Summary of reported side effects and AEs
Safety outcome
Trial group
Risk ratioa (99% CI) p-valueGabapentin Placebo
Side effects, n/N (%)
Dizziness 66/122 (54) 32/114 (28) 1.91 (1.22 to 2.99) < 0.001
Tiredness 85/129 (66) 68/120 (57) 1.12 (0.86 to 1.44) 0.27
Drowsiness 64/124 (52) 34/116 (29) 1.71 (1.09 to 2.68) 0.002
Change in mood 55/118 (47) 43/112 (38) 1.17 (0.79 to 1.74) 0.29
Change in urinary pattern 37/114 (32) 35/111 (32) 1.00 (0.61 to 1.63) 1.0
Visual disturbances 25/113 (22) 12/110 (11) 2.25 (0.99 to 5.10) 0.01
Change in skin 31/112 (28) 23/110 (21) 1.35 (0.74 to 2.50) 0.20
Different pain 33/116 (28) 37/117 (32) 0.88 (0.53 to 1.46) 0.51
Shortness of breath 17/114 (15) 11/109 (10) 1.45 (0.57 to 3.71) 0.31
AEs
SAEs, n/N (%) 10/153 (7) 3/153 (2) – 0.04
Total number of SAEs, n 12 3 – –
a Risk ratio (99% CI), adjusted for baseline score and minimisation variables. Values of < 1 favour gabapentin.
Reproduced with permission from Horne et al.51 © 2020 The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
BOX 2 Details of SAEs
Gabapentin
On the third dose of medication, onset of side effects occurred within 2 hours. Generalised myalgia
occurred especially lower limbs with pain in both groins. Auditory hallucinations and paranoid thoughts,
medication stopped. Paraesthesia in the left foot and lower leg 48 hours later. Further weakness and
myalgia of both limbs now resolving after cessation of medication.
Increased pelvic pain for a few weeks, GP prescribed oral antibiotics for a bacterial infection. Hospitalised
and ultrasound revealed mirena coil had perforated uterus. Mirena coil removed by GA. Patient recovered
Pain and migraine. USS of abdo carried out, 3 cm simple cyst seen and no further treatment required.
Lumbar puncture performed. Dural tear occurred, causing prolonged headache and monitoring in hospital.
Antibiotics and fluids given.
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Attended A&E with history of chest pain and shortness of breath for 1 week, body pain for 3 weeks and
abdominal distension for 2 months. Brief respiratory arrest following morphine. Admitted to ITU, primary
diagnosis pneumococcal pneumonia, acute kidney injury and brief respiratory arrest following morphine.
Participants condition deteriorated, had cardiac arrest twice with successful resuscitation. Ventilated
and sedated, NG tube in situ. Participant became unstable overnight, sudden loss of cardiac output,
resuscitation attempted but unsuccessful. Participant died.
SAE 1:a Participant admitted with severe abdominal pain, IV paracetamol and morphine, discharged, booked
in for ultrasound of abdomen. Scan showed gallstones, discharged with provisional diagnosis of cholecytitis.
SAE 2:a Participant admitted to hospital with acute right side abdominal pain radiating to back, more severe
than previous episodes. Treated with analgesia and booked for elective laparoscopic cholecystectomy.
Diagnosis gall stones.
Loss of consciousness, panic attacks, hallucinations, nausea, dizziness and drowsy.
SAE 1:a Severe left quadrant pain. Attended A&E was kept overnight, abdominal ultrasound, nil acute
showed, discharged.
SUSAR 1:a Pain behind left eye, noticed bloodshot then eye started blistering. Diagnosed with scleritis.
Participant admitted to hospital with severe headaches, assessed for meningitis. Lumbar puncture. Resolved
with no diagnosis.
Right sided pelvic pain for 1 week. Diagnostic laparoscopy performed and ruptured right sided cyst
removed. Participant claimed to feel unwell and feverish. Microscopy showed Escherichia coli in cyst. IV
antibiotics commenced. E. coli was laboratory error: human contamination. Participant discharged as no
growth in urine.
Anaphylactic shock. Anaphylactic throat swelling and rash sudden onset. Unable to breathe. Paramedics
called and treated at home. Likely cause: response to fish consumption.
Placebo
Pain felt in back on right side. Diagnosed with renal colic, nil seen on CT or ultrasound scan, treated with
analgesia. Haematuria noted.
Attended hospital for cough with yellow sputum, fever, neck pain and generally feeling unwell for past
7 days. Possible chest infection. Admitted, treated with IV and oral antibiotics and IV fluids. Participant
made good clinical improvement.
Dizziness with palpitations, resulting in participant collapsing, attended A&E. Participant had experienced
previous episodes prior to commencing IMP. ECG performed with normal sinus arrhythmia, discharged
home with a diagnosis of vertigo. Saw GP following episode and referred for cardiology for a 24/72 tape.
Diagnosed with postural hypotension.
A&E, accident and emergency; CT, computerised tomography; ECG, electrocardiogram; GA, general
aesthetic; ITU, intensive therapy unit; IV, intravenous; NG, nasogastric; USS, ultrasound scan.
a In patients who reported more than one SAE.
BOX 2 Details of SAEs (continued)
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Chapter 4 Results of the mechanistic
substudy
This chapter describes the mechanistic substudy of the GaPP2 clinical trial.
Introduction
Increasingly, chronic pain conditions are being acknowledged to be associated with a number of central
nervous system changes that may be responsible for generating or maintaining the pain.8 Changes within
key regions, including somatosensory, emotion regulation and components of the descending pain
modulatory system (DPMS) [including the anterior cingulate cortex (ACC), amygdala, periaqueductal
grey matter (PAG) and rostral ventromedial medulla], have been demonstrated both in conditions with a
known peripheral pathology (e.g. osteoarthritis,52–54 shoulder impingement syndrome,55 endometriosis-
associated pain)56,57 and in those for which no pathology can be found (e.g. fibromyalgia,58,59 chronic back
pain,60 irritable bowel syndrome61 and somatoform pain disorder62). CPP appears to be no different, with
reviews63,64 identifying similar changes in women with and without identified pathology. However, more
is known about irritable bowel syndrome and internal cystitis/bladder pain syndrome than about
laparoscopy-negative CPP when considering pain syndromes without identified pathology. Studies of
CPP relatively consistently demonstrate widespread hyperalgesia (an increased response to a stimulus
that was previously painful) and often allodynia (pain from a previously non-painful stimulus). The
neuroimaging studies that have explored the correlates of these sensations implicate a variety of regions
(as with other chronic pain conditions), including those involved with emotion regulation and the PAG,
as potentially involving dysfunctional pain regulatory mechanisms. However, to date, there are no
neuroimaging studies focusing on women with CPP of unknown cause. In addition, women with CPP
from a variety of causes have been shown to have hypothalamic–pituitary–adrenal axis dysfunction,
autonomic system changes and, frequently, psychological distress.63
Gabapentin is a neuromodulator for which there is evidence of efficacy in neuropathic pain conditions,65
such as postherpetic neuralgia66 and diabetic neuropathy.67 In addition, it is also used for conditions in
which there is considered to be a central component to the pain (e.g. fibromyalgia). Several animal
studies have shown reductions in central sensitisation following intrathecal administration of gabapentin.68–71
In humans, an important element of gabapentin’s efficacy appears to be supraspinal, as intrathecal
administrations are insufficient to induce analgesia.72 In anaesthetised rats, gabapentin induces a
dose-dependent increase in thalamic and PAG activation, as well as decreased activation of the limbic
system (amygdala and entorhinal cortex).35 Neuroimaging work in healthy humans has found that a
single 1800-mg dose of gabapentin during experimentally-induced central sensitisation reduced both
PAG activation and pain-induced deactivations,33 as well as insula and mesencephalic reticular
formation activation.73 This suggests that gabapentin could constitute an effective ‘antihyperalgesic’,
which supports its use in chronic pain syndromes. However, it remains to be established whether or
not gabapentin is efficacious in CPP17 or what factors may contribute to the likelihood of its success in
treating any particular person.
Randomised controlled trials of prospective analgesics always face the hurdle of strong placebo effects.
It has been proposed that we need a more mechanistic understanding of how analgesics engage pain
networks, and to relate this to symptom change within the individual, to establish true efficacy.74
Neuroimaging techniques offer a non-invasive and objective means to assess how pain networks are
altered over time in the presence of a particular treatment. Within this RCT of gabapentin for CPP, we
embedded a pre- and post-treatment fMRI study that examined brain responses to punctate stimuli.
DOI: 10.3310/eme07070 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hewitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
31
The aims were to determine (1) whether or not gabapentin, in comparison with placebo, altered brain
responses to pain; (2) whether or not this covaried with positive clinical responses over time; and
(3) whether or not pre-treatment brain responses could predict positive clinical response. In addition
to measures of subjective pain, we were concerned with our participants’ mental well-being and ability
to function in day-to-day life; a series of participant-reported validated questionnaires encompassing
these domains were, therefore, collected at baseline and after 16 weeks of treatment.
Objectives
l Determine the presence of central nervous system changes in women with CPP and no obvious
underlying pathology.
l Determine the effect of gabapentin on central pain processing in women with CPP and no
underlying pathology.
l Determine whether or not there are baseline fMRI measures that correlate with response
to treatment.
l Determine whether or not there are clinical measures that correlate with response to treatment.
Methods
Participants were drawn from those who were recruited to the GaPP2 trial from the Edinburgh region.
In total, 45 women underwent a pre-treatment baseline MRI scan, and 25 women returned for a
second scan after 12 weeks of maximum-tolerated dose of the intervention (gabapentin or placebo).
Figure 4 demonstrates group allocation and reasons for exclusion. In addition to the inclusion and
exclusion criteria of the main trial, additional exclusion criteria applied to those undergoing MRI: the
presence of implants not compatible with magnetic resonance, such as pacemakers, and claustrophobia.
Sample size
The sample size was based on data from our pilot study, GaPP1.1 In that study, 12 women had a fMRI
scan after the 12 weeks of treatment, with 11 usable data sets. Of these, five were using placebo and
six were using gabapentin. A priori region of interest (ROI) analysis demonstrated a > 1.2% difference
in the blood oxygen level-dependent signal in the PAG and a > 1.4% difference in the left posterior
insula between the groups. With a power of > 80% and p = 0.05, we, therefore, calculated that we
would need to recruit 50 women (25 per treatment group) to detect a difference in signal from key
ROIs. This sample size is greater than that used in a number of other pharmacological fMRI studies.
Magnetic resonance imaging scanning
Scanning took place at the Edinburgh Imaging Facility, Queen’s Medical Research Institute,75 using a
3T Siemens Magnetom Verio scanner (Siemens Healthcare GmbH, Erlangen, Germany). Scanning
constituted a high-resolution structural scan; functional imaging during both a resting state scan and
the application of punctate stimuli; field map acquisitions; and pseudo-continuous arterial spin labelling.
The primary outcome of interest for the mechanistic study was functional responses to punctate
stimuli, and this is the focus of this chapter. Future analyses will incorporate data from the remaining
sequences acquired.
The blood oxygen level-dependent functional images were acquired using an echoplanar T2* GRAPPA
(generalised autocalibrating partial parallel acquisition) gradient echo pulse sequence, with a repetition
time (TR) of 2500 milliseconds, an echo time (TE) of 30 milliseconds, a flip angle of 90°, a field of view
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(n = 22)
• Declined second scan, n = 2
• Follow-up questionnaires not returned, n = 3
• Technical issues during scan, n = 1
• Withdrew from trial, n = 1
• Excessive motion, n = 1
• Began GnRH/HRT therapy during the trial, n = 1
• Declined second scan, n = 5
• Follow-up questionnaires not returned, n = 3
• Technical issues during scan, n = 1
• Excessive motion, n = 1
• Underwent hysterectomy during trial, n = 1
Useable baseline MRI scan
(n = 15)
Useable post-treatment
MRI scan
(n = 13)
Underwent post-treatment
MRI scan
(n = 13)
Placebo
(n = 23)
Recruited to the mechanistic
study after being randomised
to treatment group
(n = 45)
Useable baseline MRI scan
(n = 17)
Useable post-treatment
MRI scan
(n = 12)
Underwent post-treatment
MRI scan
(n = 12)
FIGURE 4 Participant group allocation and reasons for exclusion from the study analysis. GnRH, gonadotropin-releasing hormone; HRT, hormone replacement therapy.
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(FOV) of 192 mm, 45 interleaved contiguous slices and a resolution of 3 × 3 × 3 mm. A T1-weighted
structural image was acquired using a MPRAGE (magnetisation-prepared rapid gradient echo)
sequence, with a TR of 2300 milliseconds, a TE of 2.98 milliseconds, a FOV of 256 mm, a resolution
of 1 × 1 × 1 mm and a flip angle of 9°. The punctate task was 10 minutes and 50 seconds, that is
260 volumes, the first four of which were discarded to reduce T1 saturation effects. The resting state
scan lasted 8 minutes and 20 seconds, with 200 volumes. The resting state scan was performed prior
to the punctate scan to avoid flaring participants’ pain and, thus, not truly measuring a resting state.
Gradient field maps were acquired with the same dimensions as the functional data, and TE1 (echo
time 1) 4.92 milliseconds, TE2 (echo time 2) 7.38 milliseconds. The pre-treatment scan occurred at visit 1
of the trial schedule, and the post-treatment scan between week 13 and week 16 (visit 5 of the trial
schedule). Both scans were identical and for each participant took place during the same phase of their
menstrual cycle.
The punctate scan involved the application of 39 punctate stimuli using a 300 g Touch Test von Frey
filament (Ugo Basile, Gemonio, Italy) (6.65 mm) in an event-related design. These were applied by five
researchers who had undergone appropriate training and were directed by timed auditory cues. The
mean interstimulus interval was 16 seconds, with random jitters of 2.5 seconds. Stimuli were applied
to the lower abdomen, 10 cm above the superior edge of the pubic bone. In contrast to the original
grant application, pain processing at a site distant to the clinical pain was not carried out owing to
the limitation of the equipment used for thermal stimulation of the left hand. Use of the thermal
stimulation equipment in the magnetic resonance imaging (MRI) scanner created significant noise,
which lead to distortion of the fMRI signal that was not correctable with analysis tools. We attempted
to reduce this noise by altering filters between the control and the scanner rooms, but were unable
to make a meaningful improvement. Thus, the thermal stimulation component of the paradigm was
removed. As this was at a control site rather than the site of referral of pain, it was not the primary
fMRI sequence of interest and, thus, the key data we had aimed to collect are still available (evoked
pain from a referral site and resting state data).
Outcome measures
l fMRI measures of evoked pain.
l fMRI measures of resting brain activity and connectivity.
l Post-treatment minus pre-treatment difference in fMRI measures.
l Correlation of participant-reported outcomes and fMRI measures.
Statistical analysis plan
The SAP for the mechanistic substudy was agreed between the research team, including the a priori
ROI and whole-brain analyses previously described. Further exploratory analyses of this rich data set
will continue, to improve our understanding of the main mechanistic findings.
Covariates of interest
An a priori selection of participant-reported secondary outcomes was drawn from the clinical trial and
incorporated into a series of exploratory analyses of fMRI data. NRS pain scores were taken from the
pre-treatment and post-treatment assessments for average and worst pain. Physical and mental well-
being measures were used from the Short Form Health Survey (SF-12) (with the mental component
score and physical component score). The degree to which pain interfered with daily living was taken
from the BPI. Fatigue and psychological distress were taken from the BFI and GHQ-12, respectively.
Levels of rumination, pain magnification and helplessness were taken from the PCS. Neuropathic pain
scores were taken from PainDETECT.
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Punctate functional magnetic resonance imaging data analysis
The principal analysis of the punctate fMRI data took place within Statistical Parametric Mapping (SPM12)
software [version 12 (7771); The Wellcome Centre for Human Neuroimaging, University College London,
London, UK]. Data were unwarped using the field maps and realigned to a mean image, which was
co-registered to each person’s T1-weighted structural image. This was, in turn, segmented and warped
to the Montreal Neurological Institute (MNI) space, with warp parameters applied to the co-registered
functional images. The data were finally smoothed with a 5 mm full width half maximum kernel. Quality
assurance procedures examined the data for slice spikes and significant motion (defined as a single-
volume motion exceeding half a voxel, i.e. 1.5 mm). Volumes that demonstrated problems were replaced
with a dummy volume interpolated from those acquired just before and after it, and such volumes were
represented within a nuisance regressor within the affected participants’ first-level design matrices.
If data contained more than 10 significant movement events, the participant was excluded.
For each participant, the onset of each punctate stimulus was represented as a delta function and was
convolved with the canonical haemodynamic response function, as well as its temporal and dispersion
derivatives. Nuisance regressors representing motion parameters (and dummy volumes where
applicable) were included, and the contrast for the canonical punctate regressor was taken forward
into random-effects flexible-factorial analyses. This modelled the main effects of participant, time,
treatment and the treatment group by time interaction. Incorporating the main effects of the
treatment and participant would in part account for any nuisance variance between the groups at
baseline. The main effects of treatment, time and the interaction were assessed, with clusters being
reported as significant if they achieved a whole-brain family-wise error rate (FWE) corrected threshold
of p < 0.05. To enhance sensitivity within the brainstem, a further analysis was restricted to within an
anatomical mask of the midbrain, pons and medulla, as defined by Brodmann,76 and implemented
within the WFU Pickatlas software (version 3.0.5; Wake Forest University School of Medicine,
Winston-Salem, NC, USA).77,78
For any regions demonstrating significant treatment-by-time interactions, the impact that this had
on our covariates of interest was assessed in a series of general linear models. The first eigenvariate
was extracted from significant clusters and analysed in SPSS version 24.0 (IBM SPSS Statistics for
Macintosh, IBM Corporation, Armonk, NY, USA). Each participant-reported measure was the
dependent variable, treatment group was a random factor and the changes in brain activation over
time were entered as covariates, with covariate-by-treatment interactions being modelled.
Finally, to determine whether or not punctate activation at baseline was able to predict subsequent
clinical response, the post-treatment minus pre-treatment difference for each participant-reported
measure was analysed within a general linear model using SPSS. This modelled treatment as a random
factor, and the pre-treatment punctate-induced responses from those regions demonstrating a
treatment-by-time interaction were included as covariates.
Results
Behavioural measures
Punctate stimuli were perceived as painful by some women. Pain intensity ratings after the punctate
paradigm ranged from 0 to 8 (pre-treatment scan: 3.56 ± 2.36; end-of-treatment scan: 3.12 ± 2.15).
There was no significant change in pain intensity of these stimuli between the two scans for either
group, and there was not a time × treatment interaction [placebo: scan 2 > scan 1, t(11) = –0.764,
p = 0.461; gabapentin: scan 2 > scan 1, t(11) = –0.672, p = 0.515; time × treatment interaction
F(1,22) = 0.006, p = 0.938].
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The effects of punctate stimuli
To demonstrate validity of the task, the main effects of punctate stimuli across both treatment groups
and visits are displayed in Table 19 and Figure 5. This demonstrated activation and deactivation of
regions typically associated with central pain processing, including bilateral insula, thalamus, ACC and
somatosensory cortices.
Punctate validation analyses
The main effects of time (across both treatment groups) and the effects of treatment at time 1 (post
allocation but pre intervention) were analysed. A lack of significant findings for these analyses would
support the validity of the data as a whole. There were no main effects of time that achieved statistical
significance (p > 0.551 FWE-corrected). Comparing the two treatment groups prior to treatment
showed one region of significant difference: the left postcentral gyrus [Brodmann area = 40; MNI –36,
–26, 74; peak z = 4.98; kE (cluster extent) = 134; cluster p < 0.001 FWE-corrected], which was not part
of the primary somatosensory cortex.
TABLE 19 Regions demonstrating significant activation in response to punctate stimuli across groups and visits
Region
Brodmann
area MNI co-ordinates Peak z Cluster size
Cluster
p (FWE-corrected)
Activations x y z
Right IFG/insula 13/44/47 48 18 –10 7.02 3025 < 0.001
Left SPL/postcentral gyrus 2/7/40 –30 –50 50 6.56 3264 < 0.001
Left IFG/insula/STG 13/22/47 –58 12 –4 5.84 963 < 0.001
Right IPL/SMG/MTG 2/22/40 64 –36 40 5.81 5725 < 0.001
Left cerebellum – –28 –72 –26 5.50 1560 < 0.001
Right cerebellum – 28 –48 –50 5.37 67 0.034
Left cuneus/lingual gyrus 17/18 –6 –98 10 5.30 856 < 0.001
Right ACC/SFG 8/32 4 40 24 5.10 541 < 0.001
Left MFG/precentral gyrus 6 –50 12 42 5.07 450 < 0.001
Bilateral caudate/thalamus/SN/STN – –14 –10 8 5.07 1026 < 0.001
Right SFG 8 14 50 40 5.01 105 0.003
Left MFG/IFG 9/46 –44 38 32 4.62 448 < 0.001
Right ITG 37 50 –46 –22 4.60 115 0.001
Right cuneus 18 14 –84 30 4.44 74 0.020
Left ACC 32 –12 20 28 4.23 75 0.019
Deactivations
Left pre/postcentral gyri 3/4/6 –14 –36 72 6.78 2169 < 0.001
Right medial frontal gyrus 10 2 56 –8 5.80 162 < 0.001
Left precuneus 19 –20 –86 46 4.66 124 0.001
Left postcentral gyrus 3 –38 –16 50 4.12 62 0.048
IFG, inferior frontal gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; MFG, middle frontal gyrus;
MTG, middle temporal gyrus; SFG, superior frontal gyrus; SMG, supramarginal gyrus; SN, substantia nigra;
SPL, superior parietal lobule; STN, subthalamic nucleus.
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FIGURE 5 Axial slices displaying whole-brain significant punctate-induced activation and deactivation. Displayed clusters
have p < 0.05 FWE-corrected for the whole-brain volume.
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Punctate: treatment-by-time interaction
The critical contrast of interest was to establish whether or not gabapentin altered brain activity over
time compared with changes seen in the placebo group. The treatment-by-time interaction showed
significant effects in the ACC (pregenual and anterior midcingulate subdivisions) and cuneus (Table 20
and Figure 6). Data were extracted from these regions, and post hoc t-tests confirmed that pain-evoked
activity within the ACC significantly decreased following treatment with gabapentin [t(12) = –5.763;
p < 0.001] and increased in the placebo group [t(11) = 3.784; p = 0.003]. In the cuneus, activation was
significantly decreased in the gabapentin group only [t(12) = 5.126, p < 0.001, vs. p = 0.204 for placebo].
These results remained highly significant after covarying for baseline average pain scores within a
repeated-measures analysis of covariance (p < 0.001). No areas demonstrated a significant interaction
in the brainstem mask. These findings remained significant when the pain intensity ratings obtained
after the punctate paradigm were included as a covariate.
Covariance with clinical measures of interest
The treatment-by-time interaction in ACC was related to a significant improvement in BPI pain
interferences scores [F(1,17) = 12.905; p = 0.002; see Figure 6c). For women in the gabapentin group,
those who showed larger reductions in ACC activation post treatment also had the greatest improvements
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FIGURE 6 Treatment-by-time interaction punctate activation, and associated clinical correlations. (a) Sagittal slices depict the
ACC and cuneus, from top to bottom. Both clusters are p< 0.05 FWE-corrected for the whole-brain volume; (b) extracted
activation displaying the nature of the treatment-by-time interactions, ** denotes post hoc t-test significance of < 0.005.
Error bars are 95% CI; (c) scatterplots demonstrating the relationships between changes in BPI pain interference scores and
ACC activation. For BPI pain interference score, negative changes over time indicate an improvement in symptoms.
TABLE 20 Regions showing a significant treatment-by-time interaction
Region Brodmann area MNI co-ordinates Peak z Cluster size Cluster p (FWE-corrected)
Right ACC 24/32 6, 32, 22 4.63 293 < 0.001
Right cuneus 18 16, –72, 14 4.16 66 0.013
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in their pain interference scores (Pearson’s r= 0.562; p= 0.046). The placebo group demonstrated a
markedly different pattern: the more their ACC response increased over time, the greater their
improvement on the BPI pain interference score (Pearson’s r= –0.605; p= 0.037). Cuneus changes
were not found to differentially impact on clinical improvement.
Punctate: predicting a positive response from baseline data
The ACC activation at baseline significantly predicted improvements in the physical component of
the SF-12 across both groups [physical component score, F(1,17) = 9.341; p = 0.007], but also
demonstrated a significant group interaction [F(1,17) = 5.452; p = 0.032]. Figure 7a suggests that,
although those with elevated pre-treatment ACC activation appear to improve in general, the effect is
especially pronounced in the gabapentin group.
The ACC responses at baseline also predicted improvements in neuropathic pain scores as measured by
PainDETECT [F(1,17) = 7.142; p = 0.016]. The pattern was similar to that seen in the physical component
score (see Figure 7b) in that elevated pre-treatment ACC predicted better outcomes, but this was much
more marked in those taking gabapentin.
In all cases, the black line represents the fit across both groups. For those in the gabapentin group,
the greatest improvements in (1) physical well-being (i.e. increases in SF-12 physical component
scores) and (2) neuropathic pain (i.e. decreased PainDETECTscores) are seen in those with elevated
pre-treatment ACC responses. However, bivariate correlations between the pre-treatment ACC activation
and the clinical measures at baseline did not show a significant positive relationship with PainDETECT
scores (r = 0.374; p = 0.066).
To examine this further in the clinical trial’s primary outcome measures, the study sample was split
according to the median scores of average pain (post treatment minus pre treatment). Within the
gabapentin group, those who showed the most improvement in average pain had elevated baseline
ACC activation [t(11) = 2.309; p = 0.041] and a more pronounced reduction in ACC activation after
treatment [t(11) = 2.664; p = 0.022]. This was not seen in the placebo group (p > 0.314). There were no
such effects in the cuneus or for worst pain scores.
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FIGURE 7 Predicting response to gabapentin using pre-treatment punctate activation. (a) SF-12 physical well-being
score; and (b) PainDETECT score.
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Discussion
In the mechanistic group of the GaPP2 trial, we have shown that a 12-week course of gabapentin
appears to exert an effect on the ACC in women with CPP. Those taking gabapentin show a significant
reduction in ACC responses to punctate stimuli after treatment, which in turn was associated with
improvements in pain interference scores. ACC activity at baseline also predicted those most likely
to respond to gabapentin, with participants who had the most ACC activation in response to punctate
stimuli showing the largest improvements in physical well-being and neuropathic pain. Although
these findings are in a small cohort only, the ability of neuroimaging to detect a signal of efficacy
and disentangle treatment effects from placebo is one of the strengths of a design such as this.
The ACC is known to play a role in pain processing8 and is a critical component of the DPMS.79 In
humans, pain responses during experimentally induced central sensitisation33 and multiple chronic pain
conditions53,60,61,80 are associated with increased rostral ACC activation. The ACC regions demonstrating
a treatment-by-time interaction encompassed both the most rostral aspects of the anterior midcingulate
cortex, and the pregenual subdivision. In healthy volunteers, these regions mediate placebo analgesia81
in part via mu opioid receptors.82 Interestingly, infusion of the rostral ACC with gabapentin in rats
with spinal nerve ligation reduced the aversive aspects of pain and facilitated pain relief-motivated
behaviours. This effect appeared to be dependent on endogenous opioid signalling, and was not
associated with reduced tactile allodynia itself.83 Others have proposed that pharmacological modulation
of the ACC may allow for a reduction of the distress associated with chronic pain, without impairing
the physiological function of acute pain.84 This would be consistent with the regions known roles in
processing negative emotions,85 resolving conflict86 and goal selection/maintenance.87 It is proposed that
the ACC integrates the aversiveness of pain to guide adaptive avoidant behaviours.85 It is, therefore,
significant that we observe gabapentin reducing ACC responses to pain in a way that correlates with
improvements in pain-related interference in daily living.
We also demonstrated a significant treatment-by-time interaction in the cuneus, although it is less
clear what role it may be playing. Its perfusion has been shown to be altered in migraine sufferers, in a
manner inversely related to induced pain scores.88 It also appears to relate to the affective appreciation
of pain, with pain-induced responses correlating with affective ratings in healthy volunteers.89 Here, we
found no clinical correlations.
Here, we present evidence that gabapentin acts to alter function within the DPMS, the degree to
which correlates with clinical improvement. However, we did not observe significant treatment-by-time
interactions in other DPMS brainstem structures, such as the PAG or rostral ventromedial medulla. It
may be that this study was underpowered to detect such changes, or that assessing simple differences
in activation did not capture the relationship between these structures and other DPMS regions.
Alternatively, it may be that the regions in the brainstem are too small to be detected with whole-
brain/brainstem analyses.
The evoked data are the most meaningful with regard to understanding the mechanism of drug
activity. The resting state data will be explored to understand this mechanism in more detail (informed
by the results of the evoked analysis, i.e. specific ROIs to investigate) and to further understand a
global impact of gabapentin, and how it potentially generates adverse effects.
Previous imaging studies of gabapentin in chronic pain have used a single pre-scan dose,73,90 and, as far
as we are aware, this study is the first to perform longitudinal neuroimaging pre treatment and post
treatment in a cohort of women with established CPP. To date, most pharmacological functional
imaging studies have involved male participants, in part because of concerns regarding controlling
for hormonal variation and also to avoid exposure to potentially teratogenic effects of medication.
Therefore, significant strengths of this study are that it involved a cohort of immediate relevance to
CPP and that all women underwent their post-treatment scan at a similar point in their menstrual
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cycle to the baseline scan. This study has also demonstrated the utility of incorporating pre-treatment
and post-treatment neuroimaging into a clinical trial of pain medication; we can present evidence
that gabapentin acts on chronic pain by modulating the DPMS system via ACC (in contrast to other
mechanisms implicated in CPP).63 We can also suggest that a subgroup of women, those demonstrating
pronounced ACC responses to punctate stimulation, are more likely to benefit from taking gabapentin
than others. The challenge remains to identify preclinical factors correlating with these enhanced ACC
responses that would allow responders to be identified without the need for neuroimaging. The neuropathic
PainDETECT score shows promise; however, no significant correlation with baseline ACC activation
was identified.
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Chapter 5 Discussion
Main findings
This multicentre, randomised, double-blind, placebo-controlled trial showed that in women with CPP
and no obvious pelvic pathology gabapentin was no more effective than placebo in reducing pain.
The incidence of side effects and SAEs was higher in the gabapentin group than in the placebo group.
Gabapentin appears to exert an effect on the ACC in women with CPP. Those taking gabapentin
show a significant reduction in ACC responses to punctate stimuli after treatment, which in turn was
associated with improvements in pain interference scores.
Strengths
To the best of our knowledge, this study is the only randomised placebo-controlled clinical trial to
report on the treatment of CPP with gabapentin. The robust study design, which included blinding to
treatment allocation of both participants and investigators, ensured internal validity, enabling the
results to be interpreted with confidence. Randomisation was concealed via a computer-generated
allocation sequence and achieved balanced groups with respect to pain symptoms during menstruation,
psychological functioning and concomitant hormone use, all potentially prognostic for reported pain.
Chronic pelvic pain can fluctuate or follow the menstrual cycle; therefore, eliciting a pain score at a
single time point is unlikely to capture the effect of gabapentin or reflect the women’s experience of
pain. Instead, we sought a pain score weekly over a 4-week period, asking participants to rate both
worst and average pain for the preceding week, and defined a minimum number of responses to create
a valid outcome. Although it is preferable to have a single primary outcome, a survey of our patient
involvement group found that worst pain and average pain were equally important to women. We,
therefore, chose to use dual primary outcomes and considered both worst and average pain scores.
These outcomes were considered separately and an improvement in one (or both) would conclude that
gabapentin was efficacious. All of the outcome data in the GaPP2 study were subjective or participant-
reported outcomes (rather than laboratory measurements), but the study was blinded, which reduced
the risk of incurring assessor bias.
We calculated the sample size based on a recognised minimally important difference for chronic pain
of 1 point on a 0–10 NRS, and used a SD from a comparable pilot study. We applied appropriate
adjustments to account for the dual primary outcome in both the sample size calculation and the
analysis. We recruited the target number of women and missing outcome data were as anticipated,
with follow-up rate for the dual primary outcome of 80% of women.
A high proportion of women reported taking at least half of the study drug doses throughout the trial.
The dose of gabapentin that participants received was based on individual adjustment of the dose by the
participants themselves, which reflected their perception of pain relief and side effects. Adjustments were
made in accordance with existing dosing recommendations, up to a dose of 2700mg per day, and the final
median doses ranged from 1200mg per day to 1800mg per day during the treatment phase. This is in line
with the current NeuPSIG [neuropathic pain special interest group of IASP (International Association for
the Study of Pain)] recommendations for the treatment of neuropathic pain,91 where gabapentin at a dose
of 1200–3600mg in three divided doses is a first-line treatment.
The fact that a mechanistic substudy was included is a strength of this study as it allows us to begin to
disentangle the treatment response from the placebo response, in addition to exploring the mechanism
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by which gabapentin itself might work. fMRI provides a sensitive, objective outcome measure and,
thus, allows a smaller sample size to be used than when patient-reported outcomes alone are used.
All imaging was performed at the same site on the same MRI scanner and, thus, no additional variation
with regard to data collection systems needs to be accounted for in the analysis. Furthermore, the
evoked stimulus investigated was a punctate probe, which delivers a fixed force. This is less subject to
variation than, for example, thermal stimuli, for which differences in methods of fixation to the skin or
equipment calibration can produce variation in the actual stimulus delivered. It is relatively unusual for
cohorts in such studies to be all women and, therefore, these findings may be of relevance to other
chronic pain conditions (that are more prevalent in women), given how little is known about the
mechanism of action and predictors of response to gabapentin.
Limitations
There are some limitations of our study that should be considered.
Twenty per cent of participants failed to provide pain scores at the end of treatment. Our analytical
approach involved imputation of missing responses using a recognised method, but still makes an
assumption about missing data being missing at random. Any deviation from this assumption could give
rise to different results. The sensitivity analysis was almost identical to the observed data comparison
and the CIs for both did not reach the minimally important clinical difference, so it is unlikely that a
meaningful treatment effect was missed because of missing data.
There was a potential placebo response observed in the trial. Although we acknowledge that placebo
responses are observed universally in almost all placebo-controlled randomised clinical trials,92 the response
observed in this trial is very relevant because of the side-effect profile of gabapentin and its potential
addictive properties.29 However, the trial was not designed to investigate this placebo response.
The rate of adherence to the trial regimen (women reported taking at least half of the study drug
doses throughout the trial) was high; however, this was not validated against an objective method,
such as pill counting.
The limitations of the mechanistic substudy were the small sample size, as not all women returned for
their follow-up scan despite the best efforts of the research team. Moreover, by chance, the baseline
data between the two groups were different for a number of variables. However, this has been
accounted for as much as possible in the analysis strategies.
Despite recruitment from many hospitals across the UK, the study participants are overwhelmingly
white women, which limited the generalisability of our study. CPP and dysmenorrhoea are commonly
reported across the globe,3 but barriers to seeking medically and culturally appropriate care may
exist,93 which is compounded by the well-documented under-representation in clinical trial research
among black, Asian and minority ethic populations in the UK.94
Interpretation of findings
In conclusion, our results show that gabapentin did not relieve pain or improve physical and
psychological function in women with CPP, as compared with placebo, over a course of 16 weeks.
Gabapentin was associated with higher rates of side effects than placebo.
Data from a recent review65 showed that the number needed to treat to be 6.6 (95% CI 5.0 to 10) to
achieve at least 50% pain-intensity reduction in painful diabetic neuropathy (1331 patients), and 6.7
(95% CI 5.4 to 8.7) to achieve at least 50% pain-intensity reduction in postherpetic neuralgia (2260 patients).
DISCUSSION
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The NeuPSIG review91 suggests that across all neuropathic pain conditions the number needed to treat
is 6.3 (95% CI 5.0 to 8.3), for a 50% reduction in pain intensity with an associated number needed
to harm of 25.6 (95% CI 15.3 to 78.6). The lack of treatment effect of gabapentin in women with CPP
may reflect differences in the aetiology of neuropathic pain, suggesting that recommendations from
guidelines on neuropathic pain may not apply to women with CPP.13,91 Alternatively, it may be that
women gain less benefit but are more susceptible to harm from gabapentin. It is not possible to extract
information on sexual dichotomies in responses from any of the existing systematic reviews.
Gabapentin was associated with higher rates of side effects than placebo in the trial (e.g. dizziness,
drowsiness and visual disturbances), which is consistent with other published studies.21,95 Another
recent meta-analysis of all trials for postherpetic neuralgia and painful diabetic neuropathy95 showed
that, compared with placebo, gabapentin was associated with more drowsiness (14% for gabapentin vs.
5% for placebo; p < 0.001), dizziness (19% for gabapentin vs. 7% for placebo; p < 0.001), peripheral
oedema (7% for gabapentin vs. 2% for placebo; p < 0.001) and gait disturbance or ataxia (14% for
gabapentin vs. 3% for placebo; p < 0.001).
Although more women in the placebo group were able to correctly guess their allocation at the end of
the treatment period (78/106 placebo, 54/111 gabapentin), their use of rescue medication was similar.
It cannot be concluded that women who perceived that they were taking placebo compensated by
increasing their analgesic use and, thus, negated any effect of gabapentin.
Public and patient involvement
We have been supported throughout the project by the charity Pelvic Pain Support Network (PPSN)
and, in particular, its chief executive officer. Public and patient involvement was crucial in improving
the acceptability of the GaPP2 trial and promoting engagement of gynaecologists. We engaged
with PPSN throughout, improving our understanding of the opinions and uncertainty surrounding
treatments for CPP, and the anecdotal evidence of the use of gabapentin that women have provided
here. A survey disseminated by PPSN helped us to decide to include worst and average pain scores.
We also discussed the other outcome questionnaires to be included in the trial. Members of the PPSN
commented on patient-facing materials to ensure that they were clear and comprehensive. The PPSN
promoted participating trial centres with their contact details on the website. We will engage with
PPSN regarding the dissemination of our findings, providing a Plain English summary of the findings
and the uncertainties around the evidence we have discussed here. This will be distributed via PPSN’s
website and on their social media channels. Any future research groups taking forward the research
recommendations from this project would benefit from engaging with PPSN.
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Chapter 6 Conclusions
Implications for practice
The key findings of the GaPP2 trial are clear and sufficiently generalisable to inform clinical practice.
Women with CPP and no obvious pelvic pathology should be advised that gabapentin may not alleviate
their pain and may give them unpleasant side effects.
Recommendations for future research
In our opinion, no further research is required to evaluate the role of gabapentin in the management of
women with CPP and no obvious pelvic pathology. Questions that remain unaddressed relate to the
use of other pharmacological interventions (monotherapy vs. combination therapy), physiotherapy and
cognitive–behavioural therapy for treating women with CPP. These are outlined below.
Research question
What is the clinical effectiveness, cost-effectiveness and tolerability of pharmacological monotherapy
compared with other pharmacological interventions (monotherapy vs. combination therapy),
physiotherapy and cognitive–behavioural therapy for treating women with CPP?
Population
Women with a diagnosis of CPP with and without demonstrable pathology. Demonstrable pathology
could include endometriosis, adenomyosis, adhesions, pelvic inflammatory disease, irritable bowel
syndrome, bladder pain syndrome, nerve entrapment and musculoskeletal pain.
Intervention(s)
Any pharmacological agent as monotherapy or combination therapy, physiotherapy and
cognitive–behavioural therapy. The pharmacological agents include:
l neuromodulators (e.g. amitriptyline, imipramine, nortriptyline, duloxetine, gabapentin and pregabalin)
l opiates (e.g. co-codamol, co-dydramol, dihydrocodeine, fentanyl, morphine, oxycodone, tapentadol
and tramadol)
l ovarian suppressive drugs (e.g. combined oral contraceptive pill, progestogens and gonadotrophin-
releasing hormone agonist)
l others (e.g. cannabis sativa extract).
Comparator(s)
Any of the pharmacological agents listed above as monotherapy compared with any combinations of
the pharmacological agents listed above as combination therapy compared with physiotherapy and
cognitive–behavioural therapy. Compare the treatment response across different groups of participants
with different underlying aetiology.
Outcome(s)
l Patient-reported global improvement (on a 7-point scale).
l Patient-reported improvement in daily physical and emotional functioning, including sleep (on a
9-point scale).
l At least 30% and 50% pain reduction (on a 0–10-point NRS).
l Mean change from baseline pain scores (on a 11-point NRS).
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l Withdrawal owing to adverse effects of the pharmacological agents.
l Adverse effects of the pharmacological agents.
l Health-related quality of life (e.g. EuroQol-5 Dimensions questionnaire).
Study design
l Randomised controlled trial.
l All participants should have a ‘washout’ period before assessment for inclusion in the study.
l Concomitant medications should not be allowed or should be restricted and maintained at a stable
dose during the study. Differences in concomitant pain medication usage at baseline should be
clearly described in each trial group, including details of the number of patients on different drugs.
l Rescue pain medications should either not be allowed or be accurately documented if they are used.
CONCLUSIONS
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